[sentNum: 1]<Annotation Id="160859" Type="Sentence" StartNode="4" EndNode="50">Screening for Breast Cancer CLINICAL GUIDELINE PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Clinical SemanticType:[qlco] POS:VBG POS:IN POS:NN POS:NN POS:NN POS:NN 
[sentNum: 2]<Annotation Id="160862" Type="Sentence" StartNode="114" EndNode="179">Primary Screening for Breast Cancer With Conventional Mammography PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:classical example SemanticType:[qlco] PreferredName:Primary operation SemanticType:[topp] PreferredName:Mammography SemanticType:[diap] POS:JJ POS:NN POS:NN POS:NN POS:IN POS:NN POS:IN POS:JJ 
[sentNum: 3]<Annotation Id="160863" Type="Sentence" StartNode="182" EndNode="256">Population  Women aged 40 to 49 y  Women aged 50 to 74 y  Women aged =75 y PreferredName:Woman SemanticType:[popg] PreferredName:Old age SemanticType:[popg] PreferredName:geographic population SemanticType:[qnco] PreferredName:Old age SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Old age SemanticType:[popg] POS:NNP POS:CD POS:TO POS:NNP POS:JJ POS:NNS POS:JJ POS:CD POS:NN POS:CD POS:NN POS:CD POS:TO POS:JJ POS:CD POS:NNS POS:JJ POS:NN 
[sentNum: 4]<Annotation Id="160860" Type="Sentence" StartNode="53" EndNode="62">Figure 1. POS:. POS:NNP POS:CD 
[sentNum: 5]<Annotation Id="160861" Type="Sentence" StartNode="63" EndNode="109">Screening for breast cancer: clinical summary. PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Clinical Summary SemanticType:[rnlw] POS:VBG POS:NN POS:: POS:IN POS:NN POS:. POS:JJ POS:NN 
[sentNum: 6]<Annotation Id="160866" Type="Sentence" StartNode="369" EndNode="397">Grade: B  No recommendation. PreferredName:Grade SemanticType:[clas] PreferredName:Per Billion SemanticType:[qnco] PreferredName:Recommendation SemanticType:[idcn] POS:: POS:NN POS:NNP POS:. POS:DT POS:NN 
[sentNum: 7]<Annotation Id="160867" Type="Sentence" StartNode="398" EndNode="440">Grade: I statement (insufficient evidence) PreferredName:Grade SemanticType:[clas] PreferredName:Iodides SemanticType:[inch] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Statement SemanticType:[idcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] POS:NNP POS:NN POS:CD POS:: POS:PRP POS:IN POS:JJ POS:NN 
[sentNum: 8]<Annotation Id="160864" Type="Sentence" StartNode="260" EndNode="336">Recommendation  The decision to start screening should be an individual one. PreferredName:Decision SemanticType:[menp] PreferredName:Beginning SemanticType:[tmco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:One SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Individual SemanticType:[humn] POS:DT POS:NN POS:NN POS:VBG POS:MD POS:TO POS:VB POS:JJ POS:CD POS:VB POS:DT POS:. 
[sentNum: 9]<Annotation Id="160865" Type="Sentence" StartNode="337" EndNode="368">Grade: C  Screen every 2 years. PreferredName:Grade SemanticType:[clas] PreferredName:year SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Integer +2 SemanticType:[qnco] POS:: POS:NNP POS:NNP POS:CD POS:NNS POS:NNP POS:DT POS:. 
[sentNum: 10]<Annotation Id="160870" Type="Sentence" StartNode="908" EndNode="1071">Screening Tests  Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening in the United States. PreferredName:classical example SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Screening Tests SemanticType:[hlca] PreferredName:True primary (qualifier value) SemanticType:[tmco] PreferredName:Methods SemanticType:[inpr] PreferredName:Replacement SemanticType:[ftcn] PreferredName:Film Mammography SemanticType:[diap] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:United States SemanticType:[geoa] POS:VBG POS:JJ POS:NN POS:NNS POS:JJ POS:VBN POS:NN POS:VBZ POS:RB POS:DT POS:JJ POS:NN POS:IN POS:NN POS:NN POS:NN POS:IN POS:DT POS:NNP POS:NN POS:IN POS:NNPS POS:. 
[sentNum: 11]<Annotation Id="160871" Type="Sentence" StartNode="1072" EndNode="1298">Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age &lt;50 y. PreferredName:classical example SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Diagnostic Accuracy SemanticType:[qlco] PreferredName:film (photographic) SemanticType:[mnob] PreferredName:Disease Screening SemanticType:[diap] PreferredName:SAME AS SemanticType:[clas] PreferredName:Disease Screening SemanticType:[diap] PreferredName:To SemanticType:[qlco] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Digital SemanticType:[qlco] PreferredName:Lower - spatial qualifier SemanticType:[spco] PreferredName:Specificity SemanticType:[qnco] PreferredName:High sensitivity SemanticType:[lbpr] PreferredName:Same SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] POS:JJ POS:JJ POS:VBZ POS:IN POS:NN POS:NN POS:JJ POS:NN POS:DT POS:JJ POS:RB POS:, POS:IN POS:NN POS:NN POS:VBZ POS:IN POS:JJ POS:RB POS:JJR POS:TO POS:VB POS:DT POS:JJ POS:NN POS:CC POS:NN POS:IN POS:CC POS:JJR POS:JJR POS:CD POS:NNS POS:NN POS:NN POS:. 
[sentNum: 12]<Annotation Id="160868" Type="Sentence" StartNode="446" EndNode="839">Risk Assessment  These recommendations apply to asymptomatic women aged =40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Asymptomatic SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Apply (instruction) SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Pre-existing SemanticType:[qlco] PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] PreferredName:High risk of SemanticType:[qlco] PreferredName:Lesion of breast SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Negation SemanticType:[ftcn] PreferredName:High risk of SemanticType:[qlco] PreferredName:BRCA2 Gene Mutation SemanticType:[comd] PreferredName:Neoplastic Syndromes, Hereditary SemanticType:[neop] PreferredName:Known SemanticType:[qlco] PreferredName:Mutation SemanticType:[genf] PreferredName:Radiotherapy to breast SemanticType:[topp] PreferredName:Young SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Historical aspects qualifier SemanticType:[inpr] PreferredName:Age SemanticType:[orga] POS:NN POS:NNS POS:VBP POS:NNP POS:DT POS:NNS POS:JJ POS:TO POS:JJ POS:NN POS:WP POS:JJ POS:CD POS:VB POS:JJ POS:VBP POS:RB POS:CC POS:DT POS:NN POS:NN POS:JJ POS:NN POS:RB POS:VBN POS:WP POS:VBP POS:NN POS:CC POS:JJ POS:NN POS:RB POS:IN POS:NN POS:IN POS:IN POS:NN POS:JJ POS:JJ POS:IN POS:DT POS:CD POS:JJ POS:JJ POS:NN POS:NN POS:CD POS:IN POS:DT POS:CD POS:NN POS:CC POS:NN POS:JJ POS:JJ POS:NN POS:CC POS:NN POS:CD POS:NN POS:NN POS:NN POS:IN POS:CC POS:DT POS:IN POS:DT POS:NN POS:NN POS:. POS:JJ POS:NN 
[sentNum: 13]<Annotation Id="160869" Type="Sentence" StartNode="840" EndNode="904">Increasing age is the most important risk factor for most women. PreferredName:Age SemanticType:[orga] PreferredName:risk factors SemanticType:[qnco] PreferredName:Increasing SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] POS:VBG POS:DT POS:RBS POS:NN POS:VBZ POS:NN POS:IN POS:JJ POS:NN POS:. POS:JJS POS:NNS 
[sentNum: 14]<Annotation Id="160874" Type="Sentence" StartNode="1714" EndNode="1812">The balance of benefits and harms is likely to improve as women move from their early to late 40s. PreferredName:Probably SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Late SemanticType:[tmco] PreferredName:/40 SemanticType:[tmco] PreferredName:Moving SemanticType:[orgf] PreferredName:Early SemanticType:[tmco] POS:NN POS:IN POS:DT POS:NNS POS:VBZ POS:NNS POS:CC POS:VB POS:IN POS:JJ POS:TO POS:IN POS:PRP$ POS:NNS POS:VBP POS:JJ POS:CD POS:JJ POS:TO POS:NNS POS:. 
[sentNum: 15]<Annotation Id="160875" Type="Sentence" StartNode="1816" EndNode="1938">Screening Interval  For most women, biennial mammography screening provides the best overall balance of benefit and harms. PreferredName:Woman SemanticType:[popg] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Providing (action) SemanticType:[acty] PreferredName:best (quality) SemanticType:[qlco] PreferredName:Benefits SemanticType:[qnco] POS:VBG POS:NN POS:NNS POS:, POS:IN POS:JJS POS:NN POS:VBZ POS:JJ POS:NN POS:JJ POS:NN POS:DT POS:JJS POS:CC POS:NNS POS:IN POS:NN POS:. 
[sentNum: 16]<Annotation Id="160872" Type="Sentence" StartNode="1302" EndNode="1473">Starting and Stopping Ages  For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during ages 50 to 74 y. PreferredName:Beginning SemanticType:[tmco] PreferredName:Stop brand of fluoride SemanticType:[inch, phsu] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Average SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Woman SemanticType:[popg] PreferredName:Most SemanticType:[qnco] PreferredName:Benefits SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:During SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Mammography SemanticType:[diap] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] POS:VBG POS:CC POS:IN POS:NNS POS:VBG POS:NNPS POS:IN POS:JJ POS:WP POS:VBP POS:NN POS:NN POS:NN POS:IN POS:IN POS:DT POS:, POS:JJS POS:NN POS:VBZ POS:NN POS:IN POS:NN POS:IN POS:IN POS:JJ POS:TO POS:CD POS:NNS POS:CD POS:NN POS:. 
[sentNum: 17]<Annotation Id="160873" Type="Sentence" StartNode="1474" EndNode="1713">While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Numbers SemanticType:[qnco] PreferredName:Risk SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Old SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Smaller SemanticType:[qlco] PreferredName:Biopsy SemanticType:[diap] PreferredName:Large SemanticType:[qnco] PreferredName:Numbers SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] POS:IN POS:VBG POS:NNS POS:JJ POS:NN POS:IN POS:CD POS:NN POS:CD POS:TO POS:DT POS:NN POS:MD POS:VB POS:NN POS:NN POS:IN POS:NN POS:NN POS:IN POS:, POS:DT POS:VBZ POS:JJR POS:NNS POS:VBN POS:IN POS:JJR POS:IN POS:DT POS:DT POS:NN POS:NNS POS:CC POS:NNS POS:CC POS:IN POS:JJ POS:VBZ POS:JJR POS:JJ POS:NNS POS:. 
[sentNum: 18]<Annotation Id="160878" Type="Sentence" StartNode="2147" EndNode="2277">Evidence on mammography screening in women aged =75 y is insufficient, and the balance of benefits and harms cannot be determined. PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Age SemanticType:[orga] PreferredName:Insufficient (qualifier) SemanticType:[qlco] POS:NN POS:IN POS:IN POS:NNS POS:NN POS:NN POS:CD POS:NN POS:JJ POS:JJ POS:, POS:CC POS:VBZ POS:JJ POS:IN POS:NNS POS:DT POS:NN POS:MD POS:RB POS:CC POS:NNS POS:. POS:VB POS:VBN 
[sentNum: 19]<Annotation Id="160879" Type="Sentence" StartNode="2281" EndNode="2556">Other Relevant USPSTF Recommendations  The USPSTF has made recommendations about the use of medications to reduce women&#x2019;s risk for breast cancer, as well as risk assessment, genetic counseling, and genetic testing for BRCA1- or BRCA2-related cancer (including breast cancer). PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Advice SemanticType:[hlca] PreferredName:Relevance SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Use of SemanticType:[ftcn] PreferredName:Pharmaceutical Preparations SemanticType:[phsu] PreferredName:Genetic screening method SemanticType:[lbpr] PreferredName:BRCA2 gene SemanticType:[gngm] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Genetic Counseling SemanticType:[topp] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] POS:JJ POS:NNS POS:DT POS:JJ POS:NN POS:VBN POS:NNS POS:NN POS:VBZ POS:NN POS:IN POS:IN POS:DT POS:VB POS:NNS POS:NNS POS:TO POS:NN POS:IN POS:CD POS:NNS POS:, POS:RB POS:NN POS:NN POS:NN POS:NN POS:RB POS:IN POS:NN POS:, POS:, POS:JJ POS:NN POS:IN POS:CC POS:JJ POS:: POS:CC POS:NNP POS:LS POS:: POS:JJ POS:NNP POS:LS POS:VBG POS:NN POS:NN POS:NN POS:. POS:NN POS:NN 
[sentNum: 20]<Annotation Id="160876" Type="Sentence" StartNode="1942" EndNode="2065">Balance of Benefits and Harms  The net benefit of screening mammography in women aged 40 to 49 y, while positive, is small. PreferredName:Benefits SemanticType:[qnco] PreferredName:Reticular SemanticType:[spco] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Small SemanticType:[qnco] PreferredName:/40 SemanticType:[tmco] PreferredName:Positive Finding SemanticType:[fndg] POS:IN POS:NNS POS:NN POS:DT POS:JJ POS:CC POS:VBZ POS:VBG POS:NN POS:NN POS:IN POS:JJ POS:CD POS:IN POS:NNS POS:NN POS:, POS:TO POS:CD POS:, POS:VBZ POS:IN POS:JJ POS:JJ POS:. 
[sentNum: 21]<Annotation Id="160877" Type="Sentence" StartNode="2067" EndNode="2145">The net benefit of screening mammography in women aged 50 to 74 y is moderate. PreferredName:Reticular SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Benefits SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Moderation SemanticType:[qlco] POS:DT POS:JJ POS:VBG POS:NN POS:NN POS:IN POS:JJ POS:CD POS:IN POS:NNS POS:NN POS:VBZ POS:TO POS:CD POS:JJ POS:. 
[sentNum: 22]<Annotation Id="160882" Type="Sentence" StartNode="2741" EndNode="2895">Screening Method  Primary screening with DBT  Adjunctive screening with breast ultrasonography, MRI, DBT, or other methods in women who have dense breasts PreferredName:Primary operation SemanticType:[topp] PreferredName:In addition to SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Ultrasonography, Mammary SemanticType:[diap] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Other SemanticType:[qlco] PreferredName:Methods SemanticType:[inpr] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Woman SemanticType:[popg] PreferredName:Dense breasts NOS SemanticType:[fndg] POS:VBG POS:NNP POS:IN POS:NNP POS:JJ POS:NN POS:IN POS:NN POS:JJ POS:NN POS:NNP POS:, POS:NN POS:, POS:CC POS:JJ POS:NNP POS:, POS:NNS POS:WP POS:NNS POS:IN POS:NNS POS:VBP POS:JJ 
[sentNum: 23]<Annotation Id="160883" Type="Sentence" StartNode="2899" EndNode="2933">Recommendation  No recommendation. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Recommendation SemanticType:[idcn] POS:NN POS:. POS:DT POS:NN 
[sentNum: 24]<Annotation Id="160880" Type="Sentence" StartNode="2557" EndNode="2656">These recommendations are available on the USPSTF Web site (www.uspreventiveservicestaskforce.org). PreferredName:Web Site SemanticType:[inpr] PreferredName:Internet SemanticType:[mnob] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Professional Organization or Group SemanticType:[prog] POS:DT POS:JJ POS:IN POS:NNS POS:VBP POS:NN POS:NN POS:DT POS:NNP POS:. POS:NN POS:CD POS:NN POS:NN POS:. POS:. POS:NN 
[sentNum: 25]<Annotation Id="160881" Type="Sentence" StartNode="2662" EndNode="2738">Screening for Breast Cancer With Methods Other Than Conventional Mammography PreferredName:In addition to SemanticType:[qlco] PreferredName:Methods SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:classical example SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] POS:NN POS:NN POS:VBG POS:IN POS:JJ POS:IN POS:IN POS:NNS POS:JJ POS:NN 
[sentNum: 26]<Annotation Id="160886" Type="Sentence" StartNode="3045" EndNode="3262">Benefits  From the limited data available, DBT seems to reduce recall rates (i.e., follow-up for additional imaging or testing) and increase cancer detection rates compared with conventional digital mammography alone. PreferredName:Benefits SemanticType:[qnco] PreferredName:Availability of SemanticType:[ftcn] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Internal-External Locus of Control Scale SemanticType:[diap, inpr] PreferredName:To SemanticType:[qlco] PreferredName:Mental Recall SemanticType:[menp] PreferredName:Imaging Techniques SemanticType:[diap] PreferredName:Testing SemanticType:[ftcn] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:Additional SemanticType:[ftcn] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Comparison SemanticType:[acty] PreferredName:Increase SemanticType:[ftcn] PreferredName:Cancer Detection SemanticType:[hlca] PreferredName:alone - group size SemanticType:[grpa] PreferredName:classical example SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] POS:NNS POS:IN POS:NNS POS:JJ POS:DT POS:JJ POS:VBZ POS:TO POS:, POS:NNP POS:NNS POS:VBP POS:VB POS:NN POS:LS POS:. POS:LS POS:. POS:IN POS:JJ POS:, POS:NN POS:NN POS:NN POS:NN POS:CC POS:NN POS:NN POS:CC POS:NN POS:IN POS:JJ POS:NNS POS:VBN POS:RB POS:. POS:JJ POS:NN 
[sentNum: 27]<Annotation Id="160887" Type="Sentence" StartNode="3264" EndNode="3383">Limited data suggests that ultrasonography or MRI will detect additional breast cancer in women who have dense breasts. PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Data SemanticType:[idcn] PreferredName:suggestion SemanticType:[idcn] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Additional SemanticType:[ftcn] POS:VBZ POS:IN POS:JJ POS:NNS POS:NNP POS:MD POS:NN POS:CC POS:NN POS:NN POS:VB POS:JJ POS:WP POS:VBP POS:IN POS:NNS POS:. POS:JJ POS:NNS 
[sentNum: 28]<Annotation Id="160884" Type="Sentence" StartNode="2934" EndNode="2996">Grade: I statement (insufficient evidence)  No recommendation. PreferredName:Statement SemanticType:[idcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Grade SemanticType:[clas] PreferredName:Iodides SemanticType:[inch] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] POS:NNP POS:NN POS:CD POS:: POS:PRP POS:CD POS:DT POS:JJ POS:NN POS:NN POS:. 
[sentNum: 29]<Annotation Id="160885" Type="Sentence" StartNode="2997" EndNode="3039">Grade: I statement (insufficient evidence) PreferredName:Grade SemanticType:[clas] PreferredName:Iodides SemanticType:[inch] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Statement SemanticType:[idcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] POS:NNP POS:: POS:CD POS:JJ POS:PRP POS:NN POS:NN POS:IN 
[sentNum: 30]<Annotation Id="160890" Type="Sentence" StartNode="3590" EndNode="3766">Current study designs cannot determine the degree to which the additional cases of cancer detected would have become clinically significant (i.e., the degree of overdiagnosis). PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Research Design SemanticType:[resa] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Statistical Significance SemanticType:[qnco] PreferredName:Internal-External Locus of Control Scale SemanticType:[diap, inpr] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] POS:NN POS:NNS POS:JJ POS:VB POS:DT POS:MD POS:RB POS:WDT POS:DT POS:NN POS:TO POS:IN POS:NN POS:JJ POS:NNS POS:VB POS:VBN POS:VBN POS:MD POS:NN POS:FW POS:RB POS:JJ POS:. POS:, POS:. POS:LS POS:IN POS:NN POS:DT POS:NN POS:NN POS:. 
[sentNum: 31]<Annotation Id="160891" Type="Sentence" StartNode="3768" EndNode="3849">Most positive adjunctive breast cancer screening test results are false positive. PreferredName:Most SemanticType:[qnco] PreferredName:Positive Laboratory Test Result SemanticType:[fndg] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:JJS POS:JJ POS:NN POS:VBG POS:JJ POS:NN POS:VBP POS:JJ POS:NN POS:NNS POS:JJ POS:. 
[sentNum: 32]<Annotation Id="160888" Type="Sentence" StartNode="3384" EndNode="3444">DBT also detects additional breast cancer in the short term. PreferredName:Additional SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Short-term SemanticType:[tmco] POS:NNP POS:JJ POS:NN POS:RB POS:VBZ POS:DT POS:JJ POS:NN POS:IN POS:NN POS:. 
[sentNum: 33]<Annotation Id="160889" Type="Sentence" StartNode="3448" EndNode="3589">Harms  As currently practiced in most settings, DBT exposes women to about twice the amount of radiation as conventional digital mammography. PreferredName:Practice Experience SemanticType:[menp] PreferredName:{Setting} SemanticType:[qnco] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Twice (Numerical Qualifier) SemanticType:[qnco] PreferredName:Quantity SemanticType:[qnco] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Woman SemanticType:[popg] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:classical example SemanticType:[qlco] POS:VBZ POS:IN POS:IN POS:JJS POS:RB POS:VBN POS:NNP POS:VBZ POS:NNS POS:, POS:IN POS:RB POS:NNS POS:TO POS:IN POS:NN POS:DT POS:NN POS:JJ POS:NN POS:IN POS:JJ POS:. 
[sentNum: 34]<Annotation Id="160894" Type="Sentence" StartNode="4062" EndNode="4259">For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to www.uspreventiveservicestaskforce.org. PreferredName:Summary (document) SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Full SemanticType:[qlco] PreferredName:Reviewed SemanticType:[qlco] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Documents SemanticType:[inpr] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Statement SemanticType:[idcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:GORAB gene SemanticType:[gngm] PreferredName:To SemanticType:[qlco] POS:IN POS:IN POS:DT POS:DT POS:NN POS:VBN POS:IN POS:NN POS:RB POS:NN POS:, POS:VBG POS:DT POS:NN POS:NN POS:DT POS:JJ POS:VBG POS:NNS POS:, POS:CC POS:VB POS:TO POS:, POS:VB POS:NN POS:. POS:VB POS:. POS:NN POS:. 
[sentNum: 35]<Annotation Id="160895" Type="Sentence" StartNode="4262" EndNode="4583">The USPSTF concludes that the evidence on DBT The USPSTF concludes that the evidence on ad-as a primary screening method for breast cancer is in-junctive screening for breast cancer using breast ultra-suf.cient, and the balance of bene.ts and harms can-sound, MRI, DBT, or other methods in women identi­not be determined. PreferredName:DBT gene SemanticType:[gngm] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Methods SemanticType:[inpr] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Primary operation SemanticType:[topp] PreferredName:Use of SemanticType:[ftcn] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:MALL gene SemanticType:[gngm] PreferredName:ultra SemanticType:[medd] PreferredName:cysteine desulfurase activity SemanticType:[moft] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Other SemanticType:[qlco] PreferredName:Sound - physical agent SemanticType:[npop] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Negation SemanticType:[ftcn] PreferredName:Methods SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] POS:DT POS:NN POS:DT POS:NN POS:VBZ POS:IN POS:DT POS:NN POS:IN POS:NNP POS:DT POS:NN POS:VBZ POS:IN POS:DT POS:JJ POS:IN POS:NNS POS:IN POS:NN POS:NN POS:NN POS:JJ POS:NN POS:NN POS:VBZ POS:NN POS:VBG POS:IN POS:NN POS:. POS:NN POS:NN POS:NN POS:DT POS:NN POS:, POS:CC POS:. POS:NNS POS:IN POS:NN POS:JJ POS:, POS:CC POS:VBZ POS:NNP POS:, POS:NNP POS:, POS:NNS POS:IN POS:CC POS:JJ POS:VB POS:VBN POS:NNS POS:RB POS:. 
[sentNum: 36]<Annotation Id="160892" Type="Sentence" StartNode="3853" EndNode="3969">Balance of Benefits and Harms  Evidence is insufficient, and the balance of benefits and harms cannot be determined. PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] POS:NN POS:IN POS:VBZ POS:NN POS:NNS POS:CC POS:, POS:CC POS:VBZ POS:JJ POS:IN POS:NNS POS:DT POS:NN POS:MD POS:RB POS:CC POS:NNS POS:. POS:VB POS:VBN 
[sentNum: 37]<Annotation Id="160893" Type="Sentence" StartNode="3971" EndNode="4056">Evidence is insufficient, and the balance of benefits and harms cannot be determined. PreferredName:Insufficient (qualifier) SemanticType:[qlco] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Benefits SemanticType:[qnco] POS:NN POS:, POS:CC POS:VBZ POS:JJ POS:IN POS:NNS POS:DT POS:NN POS:MD POS:RB POS:CC POS:NNS POS:. POS:VB POS:VBN 
[sentNum: 38]<Annotation Id="160898" Type="Sentence" StartNode="4687" EndNode="4694">164 No. POS:CD POS:DT POS:. 
[sentNum: 39]<Annotation Id="160899" Type="Sentence" StartNode="4695" EndNode="4719">4 &#x2022; 16 February 2016 281 POS:CD POS:CD POS:CD POS:CD POS:CD POS:NNP 
[sentNum: 40]<Annotation Id="160896" Type="Sentence" StartNode="4584" EndNode="4634">.ed to have dense breasts on an otherwise negative PreferredName:Endocrine System Findings Domain SemanticType:[idcn] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Negative SemanticType:[qlco] POS:VBN POS:TO POS:. POS:NNS POS:IN POS:VB POS:JJ POS:JJ POS:DT POS:RB 
[sentNum: 41]<Annotation Id="160897" Type="Sentence" StartNode="4637" EndNode="4686">www.annals.org Annals of Internal Medicine &#x2022; Vol. PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Volume SemanticType:[qnco] POS:NN POS:. POS:NN POS:. POS:NN POS:JJ POS:NN POS:NNS POS:IN POS:. POS:NN POS:NN 
[sentNum: 42]<Annotation Id="160902" Type="Sentence" StartNode="4784" EndNode="4902">Harms of One-Time Mammography Screening per 10 000 Women Screened: Breast Cancer Surveillance Consortium Registry Data PreferredName:one time SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Registries SemanticType:[inpr] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Data SemanticType:[idcn] POS:IN POS:NN POS:NNS POS:NN POS:IN POS:NNP POS:NN POS:NNS POS:VBN POS:CD POS:CD POS:NN POS:NNP POS:: POS:NN POS:NNP POS:NNP POS:NNP 
[sentNum: 43]<Annotation Id="160903" Type="Sentence" StartNode="4905" EndNode="4965">Variable Ages 40&#x2013;49 y Ages 50&#x2013;59 y Ages 60&#x2013;69 y Ages 70&#x2013;74 y PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] PreferredName:Variable (uniformity) SemanticType:[qlco] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Age SemanticType:[orga] PreferredName:Age SemanticType:[orga] PreferredName:Age SemanticType:[orga] POS:JJ POS:CD POS:CD POS:NNPS POS:CD POS:CD POS:CD POS:NN POS:NNPS POS:NNPS POS:CD POS:CD POS:NN POS:NN POS:NNPS POS:CD POS:CD POS:CD POS:NN POS:CD POS:CD 
[sentNum: 44]<Annotation Id="160900" Type="Sentence" StartNode="4726" EndNode="4772">CLINICAL GUIDELINE Screening for Breast Cancer PreferredName:Clinical SemanticType:[qlco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] POS:VBG POS:IN POS:JJ POS:NN POS:NN POS:NN 
[sentNum: 45]<Annotation Id="160901" Type="Sentence" StartNode="4775" EndNode="4783">Table 2. PreferredName:Data Table SemanticType:[inpr] POS:NNP POS:CD POS:. 
[sentNum: 46]<Annotation Id="160906" Type="Sentence" StartNode="5080" EndNode="5143">False-negative test results (missed cancers), n  10  11  12  13 PreferredName:Missing SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:NN POS:VBZ POS:JJ POS:NNS POS:RB POS:CD POS:VBD POS:CD POS:CD POS:, POS:NN POS:CD POS:CD 
[sentNum: 47]<Annotation Id="160907" Type="Sentence" StartNode="5151" EndNode="5205">Risk Factors That May In.uence When to Start Screening PreferredName:To SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Act Code - risk factors SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] POS:NN POS:NNS POS:IN POS:. POS:WDT POS:NNP POS:TO POS:NNP POS:NN POS:WRB POS:NNP 
[sentNum: 48]<Annotation Id="160904" Type="Sentence" StartNode="4968" EndNode="5034">False-positive test results (false alarms), n  1212  932  808  696 PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:False Positive SemanticType:[lbtr] PreferredName:False Positive SemanticType:[lbtr] POS:VBZ POS:CD POS:JJ POS:NN POS:RB POS:, POS:JJ POS:NNS POS:CD POS:CD POS:NN POS:CD POS:CD 
[sentNum: 49]<Annotation Id="160905" Type="Sentence" StartNode="5038" EndNode="5076">Breast biopsies, n  164  159  165  175 PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:NNS POS:, POS:NN POS:CD POS:CD POS:NN POS:CD POS:CD 
[sentNum: 50]<Annotation Id="160910" Type="Sentence" StartNode="5885" EndNode="6060">This approach has not been formally tested in a clinical trial; therefore, there is no directevidencethatitwouldresultinnet bene.tsimilar to that of women aged 50 to 74 years. PreferredName:Tests (qualifier value) SemanticType:[inpr] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Approach SemanticType:[spco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:no SemanticType:[idcn] PreferredName:MALL gene SemanticType:[gngm] PreferredName:year SemanticType:[tmco] POS:DT POS:NN POS:VBN POS:RB POS:VBZ POS:RB POS:DT POS:JJ POS:VBN POS:IN POS:RB POS:, POS:NN POS:: POS:DT POS:NN POS:EX POS:VBZ POS:NN POS:TO POS:NN POS:. POS:NNS POS:JJ POS:DT POS:IN POS:CD POS:NNS POS:CD POS:TO POS:. 
[sentNum: 51]<Annotation Id="160911" Type="Sentence" StartNode="6061" EndNode="6316">However, given the increased burden of disease and potential likeli­hood of bene.t, women aged 40 to 49 years who have a known .rst-degree relative (parent, child, or sibling) with breast cancer may consider initiating screening earlier than age 50 years. PreferredName:Increase SemanticType:[ftcn] PreferredName:Burden SemanticType:[idcn] PreferredName:GIVEN SemanticType:[cnce] PreferredName:hoods SemanticType:[medd] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Disease SemanticType:[dsyn] PreferredName:Potential SemanticType:[qlco] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Relative SemanticType:[qlco] PreferredName:Known SemanticType:[qlco] PreferredName:SLC22A12 gene SemanticType:[gngm] PreferredName:Sibling - RoleCode SemanticType:[inpr] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:parent SemanticType:[famg] PreferredName:Child SemanticType:[aggp] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Early SemanticType:[tmco] PreferredName:consider SemanticType:[idcn] PreferredName:Initiation SemanticType:[ftcn] PreferredName:Age-Years SemanticType:[tmco] POS:, POS:VBN POS:RB POS:NN POS:IN POS:DT POS:VBN POS:JJ POS:NN POS:NN POS:CC POS:. POS:NN POS:IN POS:NN POS:JJ POS:CD POS:, POS:NNS POS:NNS POS:WP POS:TO POS:CD POS:VBN POS:. POS:VBP POS:DT POS:CD POS:NN POS:NN POS:JJ POS:, POS:CC POS:, POS:NN POS:IN POS:NN POS:NN POS:NN POS:VB POS:VBG POS:NN POS:MD POS:IN POS:NN POS:NN POS:JJR POS:. POS:CD POS:NNS 
[sentNum: 52]<Annotation Id="160908" Type="Sentence" StartNode="5208" EndNode="5501">Advancing age is the most important risk factor for breast cancer in most women, but epidemiologic data from the BCSC suggest that having a .rst-degree rela­tive with breast cancer is associated with an approxi­mately 2-fold increased risk for breast cancer inwomen aged 40 to 49 years (2, 9). PreferredName:Age SemanticType:[orga] PreferredName:Breast Cancer Risk Factor SemanticType:[qlco] PreferredName:Advance SemanticType:[medd] PreferredName:Data SemanticType:[idcn] PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Woman SemanticType:[popg] PreferredName:epidemiologic SemanticType:[ftcn] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:suggestion SemanticType:[idcn] PreferredName:SLC22A12 gene SemanticType:[gngm] PreferredName:Increase SemanticType:[ftcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Folded structure SemanticType:[spco] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Integer +2 SemanticType:[qnco] POS:NN POS:VBZ POS:VBG POS:JJ POS:NN POS:DT POS:RBS POS:NN POS:NN POS:NN POS:IN POS:NNS POS:, POS:IN POS:JJS POS:NNS POS:IN POS:CC POS:JJ POS:VBP POS:IN POS:DT POS:NNP POS:. POS:NN POS:VBG POS:DT POS:NN POS:NN POS:JJ POS:IN POS:IN POS:DT POS:VBZ POS:VBN POS:: POS:NN POS:RB POS:LS POS:IN POS:NN POS:VBD POS:NN POS:JJ POS:CD POS:NN POS:JJ POS:NNS POS:VBP POS:TO POS:CD POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 53]<Annotation Id="160909" Type="Sentence" StartNode="5502" EndNode="5884">Further, the CISNET models suggest that for women with about a 2-fold increased risk for breast cancer, starting annual digital screening at age 40 years results in a similar harm-to-bene.t ratio (based on number of false-positive results or overdiag­nosedcasesper1000breast cancerdeaths avoided) as beginning biennial digital screening at age 50 years in average-risk women (7, 8). PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Model SemanticType:[inpr] PreferredName:Further SemanticType:[spco] PreferredName:GPR162 gene SemanticType:[gngm] PreferredName:Folded structure SemanticType:[spco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Beginning SemanticType:[tmco] PreferredName:annual screening SemanticType:[diap] PreferredName:Increased risk for cancer SemanticType:[fndg] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:/40 SemanticType:[tmco] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Digital SemanticType:[qlco] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Ratio SemanticType:[qnco] PreferredName:Base Number SemanticType:[cnce] PreferredName:Similarity SemanticType:[qlco] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Digital SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Beginning SemanticType:[tmco] PreferredName:Risk SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Average SemanticType:[qnco] POS:, POS:DT POS:RB POS:VBP POS:IN POS:NNP POS:NNS POS:IN POS:IN POS:IN POS:NNS POS:: POS:NN POS:DT POS:LS POS:IN POS:NN POS:VBD POS:NN POS:VBG POS:JJ POS:NN POS:, POS:IN POS:NN POS:JJ POS:NN POS:VBZ POS:IN POS:CD POS:NNS POS:NN POS:. POS:DT POS:JJ POS:NN POS:VBN POS:NN POS:NN POS:IN POS:JJ POS:IN POS:NN POS:JJ POS:CD POS:NNS POS:CC POS:VBD POS:RB POS:NN POS:NNS POS:JJ POS:JJ POS:IN POS:VBG POS:NN POS:CD POS:NN POS:IN POS:JJ POS:NNS POS:NNS POS:IN POS:, POS:CD POS:VBP POS:CD POS:NN POS:. 
[sentNum: 54]<Annotation Id="160914" Type="Sentence" StartNode="6879" EndNode="6898">How Often to Screen PreferredName:Frequent SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:WRB POS:RB POS:TO POS:NNP 
[sentNum: 55]<Annotation Id="160915" Type="Sentence" StartNode="6901" EndNode="6998">Once a woman has decided to begin screening, the next decision is how often to undergo screening. PreferredName:Once (schedule frequency) SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Then SemanticType:[tmco] PreferredName:To SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Decision SemanticType:[menp] PreferredName:Frequent SemanticType:[tmco] POS:RB POS:DT POS:VBN POS:TO POS:NN POS:VBZ POS:, POS:DT POS:VB POS:VBG POS:VBZ POS:WRB POS:JJ POS:NN POS:VB POS:NN POS:RB POS:TO POS:. 
[sentNum: 56]<Annotation Id="160912" Type="Sentence" StartNode="6317" EndNode="6572">Many other risk factors have been associated with breast cancer in epidemiologic studies, but most of these relationships are weak or inconsistent and would not likely in.uence how women value the tradeoffs of the potential bene.ts and harms of screening. PreferredName:Associated with SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Act Code - risk factors SemanticType:[idcn] PreferredName:Relationships SemanticType:[qlco] PreferredName:Asthenia SemanticType:[sosy] PreferredName:Epidemiologic Studies SemanticType:[resa] PreferredName:Most SemanticType:[qnco] PreferredName:Probably SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Inconsistent SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Numerical value SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] POS:JJ POS:NNS POS:VBP POS:JJ POS:NN POS:IN POS:NN POS:VBN POS:VBN POS:JJ POS:NNS POS:NN POS:IN POS:JJS POS:IN POS:, POS:CC POS:VBP POS:JJ POS:DT POS:NNS POS:CC POS:MD POS:CC POS:JJ POS:IN POS:. POS:RB POS:RB POS:NNS POS:VBP POS:NN POS:WRB POS:IN POS:DT POS:DT POS:NNS POS:. POS:NNS POS:JJ POS:NN POS:IN POS:NN POS:CC POS:NNS POS:. 
[sentNum: 57]<Annotation Id="160913" Type="Sentence" StartNode="6573" EndNode="6874">Risk calculators, such as the National Cancer Institute's Breast Cancer Risk Assessment Tool (available at www.cancer.gov/BCRISKTOOL), have good calibration between predicted and actual out­comes in groups of women but are not accurate at pre­dicting an individual woman's risk for breast cancer (10). PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Gail Risk Model SemanticType:[inpr] PreferredName:Risk SemanticType:[qlco] PreferredName:calculator SemanticType:[mnob] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:RAB3D gene SemanticType:[gngm] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Prediction SemanticType:[idcn] PreferredName:Actual SemanticType:[qlco] PreferredName:Good SemanticType:[qlco] PreferredName:Calibration SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Accurate (qualifier) SemanticType:[qlco] PreferredName:Out (direction) SemanticType:[spco] PreferredName:Women's Groups SemanticType:[popg] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Before values SemanticType:[qlco] PreferredName:Individual SemanticType:[humn] POS:NNS POS:, POS:NN POS:DT POS:NNP POS:JJ POS:IN POS:POS POS:NN POS:NNP POS:NNP POS:NNP POS:NNP POS:NN POS:NN POS:IN POS:NN POS:CD POS:JJ POS:. POS:NN POS:. POS:NN POS:CD POS:, POS:: POS:NNP POS:NN POS:IN POS:VBP POS:JJ POS:JJ POS:NNS POS:VBN POS:CC POS:IN POS:NNS POS:IN POS:NNS POS:RB POS:JJ POS:CC POS:VBP POS:DT POS:JJ POS:IN POS:VBG POS:NN POS:IN POS:NN POS:POS POS:CD POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 58]<Annotation Id="160918" Type="Sentence" StartNode="7106" EndNode="7114">Table 3. PreferredName:Table - furniture SemanticType:[mnob] POS:. POS:NNP POS:CD 
[sentNum: 59]<Annotation Id="160919" Type="Sentence" StartNode="7115" EndNode="7242">Lifetime Bene.ts and Harms of Biennial Screening Mammography per 1000 Women Screened: Model Results Compared With No Screening* PreferredName:MALL gene SemanticType:[gngm] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Model SemanticType:[inpr] PreferredName:Experimental Result SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] POS:NN POS:NNS POS:CC POS:NN POS:. POS:NNP POS:NNP POS:NNS POS:IN POS:CD POS:NNS POS:NN POS:IN POS:NNP POS:NNS POS:VBN POS:: POS:DT POS:NN POS:VBD POS:IN POS:SYM 
[sentNum: 60]<Annotation Id="160916" Type="Sentence" StartNode="6999" EndNode="7089">No clinical trials compared annual mammography with a longer interval in women of any age. PreferredName:Clinical Trial [Publication Type] SemanticType:[inpr] PreferredName:Mammography SemanticType:[diap] PreferredName:Long SemanticType:[qlco] PreferredName:Comparison SemanticType:[acty] PreferredName:Annual SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Age SemanticType:[orga] PreferredName:Data Type Interval SemanticType:[inpr] PreferredName:Present SemanticType:[qnco] POS:JJ POS:NNS POS:DT POS:NN POS:IN POS:VBN POS:JJ POS:NN POS:IN POS:DT POS:JJR POS:DT POS:NN POS:NNS POS:IN POS:. 
[sentNum: 61]<Annotation Id="160917" Type="Sentence" StartNode="7090" EndNode="7104">In the random-PreferredName:Randomization SemanticType:[resa] POS:DT POS:NN POS:IN 
[sentNum: 62]<Annotation Id="160922" Type="Sentence" StartNode="7334" EndNode="7379">Life-years gained  152 (99&#x2013;195)  122 (75&#x2013;154) PreferredName:Life SemanticType:[idcn] PreferredName:year SemanticType:[tmco] PreferredName:Gain SemanticType:[qnco] POS:NNS POS:VBD POS:CD POS:NN POS:CD POS:CD POS:CD POS:CD POS:CD POS:NN POS:CD POS:NN POS:CD POS:NN 
[sentNum: 63]<Annotation Id="160923" Type="Sentence" StartNode="7383" EndNode="7447">False-positive test results, n  1529 (1100&#x2013;1976)  953 (830&#x2013;1325) PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:False Positive SemanticType:[lbtr] POS:NNS POS:, POS:JJ POS:NN POS:CD POS:CD POS:NN POS:CD POS:NN POS:CD POS:CD POS:CD POS:CD POS:CD POS:NN POS:CD POS:NN 
[sentNum: 64]<Annotation Id="160920" Type="Sentence" StartNode="7245" EndNode="7279">Variable Ages Ages 40&#x2013;74 y 50&#x2013;74 y PreferredName:Variable (uniformity) SemanticType:[qlco] PreferredName:Age SemanticType:[orga] PreferredName:Age SemanticType:[orga] PreferredName:/40 SemanticType:[tmco] POS:NNPS POS:NNPS POS:JJ POS:CD POS:NN POS:CD POS:CD POS:CD POS:NN POS:CD POS:CD 
[sentNum: 65]<Annotation Id="160921" Type="Sentence" StartNode="7282" EndNode="7330">Fewer breast cancer deaths, n  8 (5&#x2013;10)  7 (4&#x2013;9) PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Integer +5 SemanticType:[qnco] POS:NN POS:NNS POS:JJR POS:NN POS:CD POS:NN POS:, POS:NN POS:CD POS:NN POS:CD POS:CD POS:CD POS:CD POS:CD POS:NN POS:CD POS:NN 
[sentNum: 66]<Annotation Id="160926" Type="Sentence" StartNode="7577" EndNode="7616">* Values reported are medians (ranges). PreferredName:Values SemanticType:[qlco] PreferredName:Range SemanticType:[qnco] PreferredName:Reporting SemanticType:[hlca] PreferredName:Midline (qualifier value) SemanticType:[spco] POS:SYM POS:VBP POS:NNS POS:NNS POS:VBN POS:RB POS:. POS:CD POS:NNS 
[sentNum: 67]<Annotation Id="160927" Type="Sentence" StartNode="7619" EndNode="7801">ized trials that demonstrated the effectiveness of mam­mography in reducing breast cancer deaths in women aged 40 to 74 years, screening intervals ranged from 12 to 33 months (2, 3). PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Within SemanticType:[spco] PreferredName:Reduced SemanticType:[qlco] PreferredName:Effectiveness SemanticType:[qlco] PreferredName:Mammography SemanticType:[diap] PreferredName:Old age SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Interval SemanticType:[tmco] PreferredName:Sample Range SemanticType:[qnco] PreferredName:year SemanticType:[tmco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:month SemanticType:[tmco] PreferredName:2+ Score SemanticType:[qnco] POS:WDT POS:VBD POS:VBN POS:NNS POS:IN POS:NN POS:DT POS:NN POS:NN POS:NN POS:IN POS:VBG POS:NNS POS:JJ POS:NNS POS:IN POS:CD POS:NNS POS:CD POS:TO POS:NNS POS:VBD POS:, POS:VBG POS:TO POS:CD POS:IN POS:CD POS:CD POS:, POS:NNS POS:VBP POS:. POS:CD POS:NN 
[sentNum: 68]<Annotation Id="160924" Type="Sentence" StartNode="7451" EndNode="7511">Unnecessary breast biopsies, n  213 (153&#x2013;276)  146 (121&#x2013;205) PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] POS:NN POS:NNS POS:JJ POS:CD POS:NN POS:, POS:NN POS:CD POS:NN POS:CD POS:NN POS:CD POS:NN POS:CD POS:NN POS:CD POS:NN 
[sentNum: 69]<Annotation Id="160925" Type="Sentence" StartNode="7515" EndNode="7569">Overdiagnosed breast tumors, n  21 (12&#x2013;38)  19 (11&#x2013;34) PreferredName:N not otherwise specified Antibody SemanticType:[aapp, imft] PreferredName:Mammary Neoplasms SemanticType:[neop] POS:JJ POS:NN POS:NN POS:CD POS:NNS POS:, POS:NN POS:CD POS:CD POS:CD POS:NN POS:CD POS:CD POS:CD POS:NN POS:CD POS:CD 
[sentNum: 70]<Annotation Id="160930" Type="Sentence" StartNode="8212" EndNode="8481">Regardless of the starting age for screening, the models consistently predict a small incremental in­crease in the number of breast cancer deaths averted when moving from biennial to annual mammography, but also a large increase in the number of harms (Table 4) (7, 8). PreferredName:Age SemanticType:[orga] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Regardless SemanticType:[qlco] PreferredName:Beginning SemanticType:[tmco] PreferredName:Increment SemanticType:[qnco] PreferredName:Within SemanticType:[spco] PreferredName:Model SemanticType:[inpr] PreferredName:A little bit SemanticType:[inpr] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Moving SemanticType:[orgf] PreferredName:Numbers SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Large SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Numbers SemanticType:[qnco] PreferredName:Table - furniture SemanticType:[mnob] POS:DT POS:VBG POS:RB POS:IN POS:NN POS:, POS:NN POS:IN POS:RB POS:VBP POS:DT POS:NNS POS:JJ POS:NN POS:DT POS:JJ POS:NN POS:IN POS:IN POS:DT POS:NNS POS:VBN POS:NN POS:NN POS:IN POS:JJ POS:WRB POS:VBG POS:NN POS:, POS:TO POS:JJ POS:DT POS:JJ POS:CC POS:RB POS:DT POS:NN POS:NN POS:IN POS:VBP POS:NNP POS:IN POS:NNS POS:NN POS:CD POS:CD POS:CD POS:NN POS:. POS:, POS:CD 
[sentNum: 71]<Annotation Id="160931" Type="Sentence" StartNode="8482" EndNode="8609">The USPSTF concludes that for most women, biennial mammography screening provides the best overall balance of bene.t and harms. PreferredName:Conclude Resin SemanticType:[bodm, orch] PreferredName:Woman SemanticType:[popg] PreferredName:best (quality) SemanticType:[qlco] PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Ability to balance SemanticType:[fndg] PreferredName:MALL gene SemanticType:[gngm] POS:VBZ POS:IN POS:DT POS:NN POS:NNS POS:, POS:IN POS:JJS POS:NN POS:VBZ POS:JJ POS:NN POS:JJ POS:NN POS:DT POS:JJS POS:. POS:NN POS:IN POS:NN POS:. POS:CC POS:NNS 
[sentNum: 72]<Annotation Id="160928" Type="Sentence" StartNode="7802" EndNode="7975">There was no clear trend for greater bene.t in trials of annual mammography, but other differences between the trials preclude certainty that no difference in bene.t exists. PreferredName:no SemanticType:[idcn] PreferredName:Largest SemanticType:[qnco] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Clear SemanticType:[qlco] PreferredName:trend SemanticType:[tmco] PreferredName:Annual SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Within SemanticType:[spco] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Certain (qualifier value) SemanticType:[qlco] PreferredName:No status change SemanticType:[fndg] PreferredName:Clinical Trial, Other SemanticType:[resa] PreferredName:Delta (difference) SemanticType:[qnco] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Exist SemanticType:[cnce] POS:EX POS:JJ POS:NN POS:VBD POS:DT POS:NN POS:. POS:IN POS:JJR POS:NNS POS:IN POS:NN POS:IN POS:, POS:CC POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NNS POS:NN POS:IN POS:NNS POS:VBP POS:IN POS:NN POS:DT POS:NN POS:VBZ POS:. POS:. POS:NN 
[sentNum: 73]<Annotation Id="160929" Type="Sentence" StartNode="7976" EndNode="8209">Available observa­tional evidence evaluating the effects of varying mam­mography intervals found no difference in the number ofbreast cancerdeaths between womenaged50years or older who were screened biennially versus annually (2, 3). PreferredName:Availability of SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Interval SemanticType:[tmco] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Effect SemanticType:[qlco] PreferredName:Numbers SemanticType:[qnco] PreferredName:Old SemanticType:[tmco] PreferredName:Present SemanticType:[qnco] PreferredName:No status change SemanticType:[fndg] PreferredName:2+ Score SemanticType:[qnco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] POS:NN POS:VBG POS:JJ POS:JJ POS:IN POS:VBG POS:DT POS:NNS POS:VBD POS:DT POS:NN POS:NNS POS:DT POS:NN POS:NN POS:IN POS:IN POS:JJ POS:NN POS:NNS POS:CC POS:JJR POS:CD POS:NNS POS:VBN POS:RB POS:WP POS:VBD POS:NN POS:CD POS:CC POS:RB POS:NN POS:. POS:, POS:CD 
[sentNum: 74]<Annotation Id="160934" Type="Sentence" StartNode="8720" EndNode="9011">In its 2009 recommendation (11), the USPSTF extended the recommendation for screening mammography to age 74 years based on the extrapo­lation that much of the bene.t seen in women aged 60 to 69 years should continue in this age range, and modeling done at the time supported this assumption. PreferredName:Recommendation SemanticType:[idcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Age-Years SemanticType:[tmco] PreferredName:Extension SemanticType:[ftcn] PreferredName:Recommendation SemanticType:[idcn] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Seen SemanticType:[qlco] PreferredName:Basis - conceptual entity SemanticType:[ftcn] PreferredName:Latia SemanticType:[euka] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:year SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Old age SemanticType:[popg] PreferredName:Range SemanticType:[qnco] PreferredName:Modeling SemanticType:[inpr, resa] PreferredName:Continuous SemanticType:[idcn] PreferredName:Age SemanticType:[orga] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Stop (qualifier value) SemanticType:[tmco] PreferredName:Time SemanticType:[tmco] POS:PRP$ POS:CD POS:IN POS:CD POS:NN POS:NN POS:CD POS:NNP POS:VBD POS:, POS:DT POS:IN POS:VBG POS:DT POS:NN POS:NN POS:CD POS:NN POS:TO POS:IN POS:DT POS:NNS POS:VBN POS:RB POS:IN POS:NN POS:WDT POS:. POS:NN POS:DT POS:NN POS:NNS POS:JJ POS:VBN POS:IN POS:CD POS:NNS POS:CD POS:TO POS:IN POS:DT POS:MD POS:VB POS:, POS:CC POS:NN POS:NN POS:IN POS:DT POS:NN POS:VBN POS:DT POS:NN POS:NN POS:VBD POS:. 
[sentNum: 75]<Annotation Id="160935" Type="Sentence" StartNode="9012" EndNode="9214">Current CISNET models suggest that women aged 70 to 74 years with moderate to severe comorbid condi­tions that negatively affect their life expectancy are unlikely to bene.t from mammography (7, 8, 12). PreferredName:Current (present time) SemanticType:[tmco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Model SemanticType:[inpr] PreferredName:In addition to SemanticType:[qlco] PreferredName:Moderate to severe SemanticType:[qlco] PreferredName:Old age SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Life Expectancy SemanticType:[grpa] PreferredName:Unlikely SemanticType:[cnce] PreferredName:Comorbidity SemanticType:[idcn] PreferredName:Affect (mental function) SemanticType:[menp] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Mammography SemanticType:[diap] POS:NNP POS:NNS POS:JJ POS:NNS POS:JJ POS:VBP POS:IN POS:CD POS:NNS POS:CD POS:TO POS:TO POS:JJ POS:IN POS:JJ POS:WDT POS:RB POS:NN POS:NNS POS:NN POS:NN POS:VBP POS:PRP$ POS:TO POS:NN POS:VBP POS:JJ POS:IN POS:NN POS:. POS:NN POS:, POS:CD POS:NN POS:CD POS:NN POS:. POS:, POS:CD 
[sentNum: 76]<Annotation Id="160932" Type="Sentence" StartNode="8614" EndNode="8649">When to Consider Stopping Screening PreferredName:To SemanticType:[qlco] PreferredName:consider SemanticType:[idcn] PreferredName:Stop brand of fluoride SemanticType:[inch, phsu] PreferredName:Trial Screening SemanticType:[resa] POS:WRB POS:NNP POS:NNP POS:TO POS:VB 
[sentNum: 77]<Annotation Id="160933" Type="Sentence" StartNode="8652" EndNode="8719">Clinical trial data for women aged 70 to 74 years are inconclusive. PreferredName:Data SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Inconclusive (qualifier value) SemanticType:[qlco] PreferredName:Old age SemanticType:[popg] PreferredName:year SemanticType:[tmco] POS:NNS POS:IN POS:JJ POS:NN POS:CD POS:TO POS:NNS POS:JJ POS:VBP POS:JJ POS:CD POS:NNS POS:. 
[sentNum: 78]<Annotation Id="160938" Type="Sentence" StartNode="9610" EndNode="9651">Screening in Women Aged 75 Years or Older PreferredName:Disease Screening SemanticType:[diap] PreferredName:year SemanticType:[tmco] PreferredName:Old SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Old age SemanticType:[popg] POS:IN POS:NNS POS:NN POS:NNS POS:CC POS:VBD POS:CD POS:JJR 
[sentNum: 79]<Annotation Id="160939" Type="Sentence" StartNode="9654" EndNode="9793">The USPSTF found insuf.cient evidence to assess the balance of bene.ts and harms of screening mam­mography in women aged 75 years or older. PreferredName:Assessed SemanticType:[acty] PreferredName:Balanced - adjective SemanticType:[ftcn] PreferredName:Present SemanticType:[qnco] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Old SemanticType:[tmco] PreferredName:Old age SemanticType:[popg] PreferredName:year SemanticType:[tmco] POS:NNP POS:VBD POS:DT POS:NN POS:NN POS:NN POS:. POS:DT POS:NN POS:TO POS:VB POS:. POS:NNS POS:IN POS:NN POS:IN POS:VBG POS:CC POS:NNS POS:NNS POS:JJ POS:NN POS:IN POS:CC POS:JJR POS:CD POS:NNS POS:. 
[sentNum: 80]<Annotation Id="160936" Type="Sentence" StartNode="9215" EndNode="9302">Mod­erate comorbid conditions include cardiovascular dis­ease, paralysis, and diabetes. PreferredName:Diabetes Mellitus, Non-Insulin-Dependent SemanticType:[dsyn] PreferredName:Co-morbid conditions SemanticType:[fndg] PreferredName:Discontinued SemanticType:[fndg] PreferredName:Comfort SemanticType:[menp] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Cardiovascular system SemanticType:[bdsy] PreferredName:Paralysed SemanticType:[fndg] PreferredName:Diabetes Mellitus SemanticType:[dsyn] POS:NNS POS:VBP POS:NN POS:NN POS:, POS:NN POS:JJ POS:NN POS:NN POS:. POS:, POS:CC 
[sentNum: 81]<Annotation Id="160937" Type="Sentence" StartNode="9303" EndNode="9605">Severe comorbid condi­tions include (but are not limited to) AIDS, chronic obstructive pulmonary disease, liver disease, chronic renal failure, dementia, congestive heart failure, and combinations of moderate comorbid conditions, as well as myocardial infarction, ulcer, and rheumatologic disease (12). PreferredName:Severe (severity modifier) SemanticType:[qlco] PreferredName:Comorbidity SemanticType:[idcn] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Acquired Immunodeficiency Syndrome SemanticType:[dsyn] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Kidney Failure, Chronic SemanticType:[dsyn] PreferredName:Dementia SemanticType:[mobd] PreferredName:Chronic Obstructive Airway Disease SemanticType:[dsyn] PreferredName:Liver diseases SemanticType:[dsyn] PreferredName:Moderation SemanticType:[qlco] PreferredName:Co-morbid conditions SemanticType:[fndg] PreferredName:Congestive heart failure SemanticType:[dsyn] PreferredName:Combinations (Undergarment) SemanticType:[mnob] PreferredName:Collagen Diseases SemanticType:[dsyn] PreferredName:Myocardial infarction:Finding:Point in time:^Patient:Ordinal SemanticType:[clna] PreferredName:Ulcer SemanticType:[patf] POS:NNS POS:VBP POS:JJ POS:NN POS:VBP POS:RB POS:NN POS:CC POS:VB POS:NNP POS:VBN POS:TO POS:JJ POS:JJ POS:, POS:JJ POS:NN POS:NN POS:NN POS:, POS:JJ POS:NN POS:, POS:JJ POS:, POS:JJ POS:, POS:NN POS:, POS:CC POS:NN POS:NN POS:JJ POS:NN POS:NNS POS:IN POS:RB POS:RB POS:NNS POS:, POS:NN POS:, POS:IN POS:JJ POS:CC POS:JJ POS:NN POS:, POS:CD POS:NN POS:NN POS:NN POS:. 
[sentNum: 82]<Annotation Id="160942" Type="Sentence" StartNode="10076" EndNode="10083">164 No. POS:DT POS:. POS:CD 
[sentNum: 83]<Annotation Id="160943" Type="Sentence" StartNode="10084" EndNode="10119">4 &#x2022; 16 February 2016 www.annals.org PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] POS:CD POS:NNP POS:CD POS:CD POS:. POS:NN POS:CD POS:NN POS:. POS:NN 
[sentNum: 84]<Annotation Id="160940" Type="Sentence" StartNode="9794" EndNode="10032">CISNET models suggestthat biennial mammography screening may potentially continue to offer a net bene.t after age 74yearsamongthosewithnoorlowcomorbidity(7,8), but no randomized trials of screening included women in this age group (2, 3). PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Continuous SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Model SemanticType:[inpr] PreferredName:Screening mammography SemanticType:[topp] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Age SemanticType:[orga] PreferredName:Tonsillectomy and adenoidectomy SemanticType:[topp] PreferredName:Reticular SemanticType:[spco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:no SemanticType:[idcn] PreferredName:Clinical Trials, Randomized SemanticType:[inpr, resa] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Human Age Group SemanticType:[aggp] POS:NNS POS:JJ POS:NNP POS:NN POS:MD POS:JJ POS:NN POS:TO POS:VB POS:RB POS:VB POS:NN POS:. POS:DT POS:JJ POS:NN POS:CD POS:NN POS:IN POS:CD POS:, POS:NN POS:NN POS:, POS:CC POS:CD POS:NN POS:NNS POS:IN POS:DT POS:VBN POS:NNS POS:IN POS:NN POS:VBD POS:NN POS:CD POS:DT POS:NN POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 85]<Annotation Id="160941" Type="Sentence" StartNode="10037" EndNode="10075">284 Annals of Internal Medicine &#x2022; Vol. PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Volume SemanticType:[qnco] POS:NNS POS:IN POS:CD POS:NN POS:NN POS:JJ POS:NN POS:. 
[sentNum: 86]<Annotation Id="160946" Type="Sentence" StartNode="10234" EndNode="10492">1.06 to 3.39]) or a breast tumor larger than 20 mm (odds ratio, 2.39 [CI, 1.37 to 3.18]) in women aged 40 to 49 years with extremely dense breasts (BI-RADS cat­egory d) compared with annual screening; this risk was not seen in women aged 50 to 74 years (19). PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Odds Ratio SemanticType:[qnco] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Mammary Neoplasms SemanticType:[neop] PreferredName:Greater SemanticType:[qnco] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:1+ Score, WHO SemanticType:[clas] PreferredName:Woman SemanticType:[popg] PreferredName:Breast Imaging Reporting and Data System SemanticType:[diap] PreferredName:Felis catus SemanticType:[mamm] PreferredName:year SemanticType:[tmco] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Risk SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:annual screening SemanticType:[diap] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Seen SemanticType:[qlco] PreferredName:Woman SemanticType:[popg] POS:LS POS:. POS:CD POS:. POS:CD POS:TO POS:NN POS:CC POS:CD POS:CD POS:NN POS:JJR POS:DT POS:NN POS:NN POS:NN POS:IN POS:CD POS:, POS:CD POS:NNS POS:NN POS:CD POS:NN POS:. POS:CD POS:. POS:CD POS:, POS:CD POS:. POS:CD POS:TO POS:CD POS:IN POS:NNS POS:CD POS:NN POS:TO POS:CD POS:JJ POS:CD POS:RB POS:JJ POS:NNS POS:IN POS:NN POS:NN POS:NNS POS:VBP POS:VBN POS:IN POS:NN POS:CD POS:: POS:DT POS:JJ POS:NN POS:RB POS:VBN POS:NN POS:VBD POS:JJ POS:CD POS:IN POS:NNS POS:NNS POS:VBP POS:TO POS:CD POS:. POS:CD POS:CD 
[sentNum: 87]<Annotation Id="160947" Type="Sentence" StartNode="10493" EndNode="10582">No signif­icant differences in lymph node involvement were ob­served in either age group. PreferredName:Human Age Group SemanticType:[aggp] PreferredName:Action Code - No change SemanticType:[inpr] PreferredName:Lymph Node Involvement SemanticType:[fndg] POS:DT POS:IN POS:NN POS:JJ POS:NNS POS:VBD POS:VBN POS:NN POS:NN POS:NN POS:NN POS:IN POS:CC POS:. 
[sentNum: 88]<Annotation Id="160944" Type="Sentence" StartNode="10124" EndNode="10170">CLINICAL GUIDELINE Screening for Breast Cancer PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Clinical stage finding SemanticType:[tmco] PreferredName:Guideline [Publication Type] SemanticType:[inpr] POS:JJ POS:NN POS:NN POS:NN POS:VBG POS:IN 
[sentNum: 89]<Annotation Id="160945" Type="Sentence" StartNode="10173" EndNode="10231">stage cancer (stage IIB or greater) (odds ratio, 2.39 [CI, PreferredName:Stage 2 lower case b SemanticType:[clas] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Greater SemanticType:[qnco] PreferredName:Odds Ratio SemanticType:[qnco] POS:CD POS:NN POS:NN POS:NN POS:JJR POS:CD POS:NN POS:CC POS:NN POS:, POS:NN POS:NNS POS:CD POS:CD POS:CD POS:. POS:NN POS:, 
[sentNum: 90]<Annotation Id="160950" Type="Sentence" StartNode="10979" EndNode="11141">Screening more frequently (that is, an­nually vs. biennially) further increases the probability that a woman will experience one of these screening-related harms. PreferredName:Disease Screening SemanticType:[diap] PreferredName:More SemanticType:[ftcn] PreferredName:Increase SemanticType:[ftcn] PreferredName:Probability SemanticType:[qnco] PreferredName:Frequent SemanticType:[tmco] PreferredName:Further SemanticType:[spco] PreferredName:One SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Practice Experience SemanticType:[menp] PreferredName:Relationships SemanticType:[qlco] POS:VBG POS:RBR POS:DT POS:VBZ POS:RB POS:VBP POS:CC POS:. POS:, POS:RB POS:JJ POS:NNS POS:RB POS:CD POS:IN POS:DT POS:DT POS:NN POS:VB POS:CD POS:NN POS:MD POS:JJ POS:NNS POS:IN POS:DT POS:. 
[sentNum: 91]<Annotation Id="160951" Type="Sentence" StartNode="11142" EndNode="11393">Data from the BCSC indicate that the cumulative probability that a woman aged 40 to 49 years with extremely dense breasts screened annually for a decade will receive a false-positive result is about 69%, compared with about 21% for biennial screening. PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Data SemanticType:[idcn] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:/40 SemanticType:[tmco] PreferredName:Probability SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Annual SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Arabic numeral 69 SemanticType:[inpr] PreferredName:Decade SemanticType:[qnco] PreferredName:Receive SemanticType:[qlco] PreferredName:Comparison SemanticType:[acty] PreferredName:Disease Screening SemanticType:[diap] POS:IN POS:DT POS:NNS POS:IN POS:DT POS:NNP POS:VBP POS:IN POS:DT POS:JJ POS:NN POS:CD POS:TO POS:NN POS:JJ POS:IN POS:RB POS:CD POS:NNS POS:VBN POS:RB POS:JJ POS:NNS POS:NN POS:MD POS:IN POS:DT POS:JJ POS:NN POS:VB POS:DT POS:CD POS:NN POS:VBZ POS:IN POS:IN POS:RB POS:, POS:VBN POS:IN POS:JJ POS:CD POS:NN POS:NN POS:. 
[sentNum: 92]<Annotation Id="160948" Type="Sentence" StartNode="10583" EndNode="10759">Information about morbid­ity or mortality end points is not available, so whether these women ultimately fared any differently in their clinical outcomes is not known (17, 19). PreferredName:Information SemanticType:[idcn] PreferredName:End Point SemanticType:[qlco] PreferredName:Not available SemanticType:[idcn] PreferredName:Morbidity - disease rate SemanticType:[qnco] PreferredName:Mortality Vital Statistics SemanticType:[qnco] PreferredName:Clinical SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:Any SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Known SemanticType:[qlco] POS:IN POS:NN POS:NN POS:NN POS:NNS POS:CC POS:NN POS:JJ POS:, POS:VBZ POS:RB POS:DT POS:NNS POS:IN POS:IN POS:DT POS:RB POS:RB POS:VBD POS:JJ POS:NNS POS:IN POS:PRP$ POS:VBN POS:NN POS:VBZ POS:RB POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 93]<Annotation Id="160949" Type="Sentence" StartNode="10762" EndNode="10978">All women aged 40 to 74 years with increased breast density are at increased risk for a false-positive result, an unnecessary breast biopsy, or a false-negative result compared with women with average breast density. PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Decreased translucency SemanticType:[fndg] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:/40 SemanticType:[tmco] PreferredName:year SemanticType:[tmco] PreferredName:Risk SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:are unit of measure SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Woman SemanticType:[popg] PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:False Negative Result Medical Device Problem SemanticType:[fndg] PreferredName:Average SemanticType:[qnco] PreferredName:Breast Density SemanticType:[clna] POS:NNS POS:JJ POS:DT POS:CD POS:NNS POS:CD POS:TO POS:NN POS:NN POS:IN POS:VBN POS:VBN POS:NN POS:VBP POS:IN POS:JJ POS:NN POS:IN POS:DT POS:JJ POS:NN POS:, POS:DT POS:CC POS:DT POS:NN POS:, POS:VBN POS:IN POS:JJ POS:NN POS:JJ POS:NN POS:NNS POS:IN POS:NN POS:. 
[sentNum: 94]<Annotation Id="160954" Type="Sentence" StartNode="11536" EndNode="11554">Potential Bene.ts. PreferredName:MALL gene SemanticType:[gngm] PreferredName:Potential SemanticType:[qlco] POS:. POS:NNS POS:JJ POS:NN POS:. 
[sentNum: 95]<Annotation Id="160955" Type="Sentence" StartNode="11555" EndNode="11944">Current evidence on adjunctive screeningisverylimited,butitsuggeststhatfor women identi.ed to have dense breasts on an otherwise neg­ative mammogram, ultrasonography or MRI will detect additional breast cancer but will also result in a higher numberoffalse-positiveresults.Data onDBTin women with dense breasts are limited, but in the short term, DBT also detects additional breast cancer. PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Endocrine System Findings Domain SemanticType:[idcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Mammography SemanticType:[diap] PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Negative SemanticType:[qlco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Detected (finding) SemanticType:[fndg] PreferredName:Data SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Result SemanticType:[ftcn] PreferredName:High SemanticType:[qlco] PreferredName:Butting SemanticType:[mobd] PreferredName:Short-term SemanticType:[tmco] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Additional SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Detected (finding) SemanticType:[fndg] POS:NN POS:IN POS:JJ POS:, POS:NN POS:JJ POS:VBN POS:. POS:VBN POS:NNS POS:VBP POS:JJ POS:NNS POS:TO POS:VB POS:RB POS:JJ POS:IN POS:DT POS:NN POS:CC POS:NN POS:, POS:VB POS:JJ POS:NNP POS:MD POS:CC POS:MD POS:NN POS:NN POS:IN POS:DT POS:RB POS:VB POS:. POS:NNP POS:JJR POS:NNS POS:IN POS:JJ POS:NNP POS:NNS POS:VBN POS:, POS:NNS POS:VBP POS:DT POS:JJ POS:CC POS:IN POS:NNP POS:RB POS:NN POS:, POS:NN POS:NN POS:VBZ POS:JJ POS:. 
[sentNum: 96]<Annotation Id="160952" Type="Sentence" StartNode="11394" EndNode="11508">Similarly, unnecessary breast biopsy rates are 12% for annual screening versus 3% for biennial screening (17, 18). PreferredName:Biopsy of breast SemanticType:[diap] PreferredName:Rate SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:annual screening SemanticType:[diap] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] POS:RB POS:, POS:NN POS:NNS POS:JJ POS:NN POS:NN POS:IN POS:VBP POS:CD POS:CC POS:CD POS:JJ POS:NN POS:JJ POS:NN POS:NN POS:IN POS:, POS:CD POS:NN POS:CD POS:NN POS:. 
[sentNum: 97]<Annotation Id="160953" Type="Sentence" StartNode="11511" EndNode="11531">Adjunctive Screening PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Disease Screening SemanticType:[diap] POS:JJ POS:NN 
[sentNum: 98]<Annotation Id="160958" Type="Sentence" StartNode="12295" EndNode="12667">Although adjunctive screening may de­tectmorebreastcancer,these cancersmayfallinto1of 3 categories: 1) those for which earlier detection leads to improved outcomes, 2) those that would have had thesameoutcomewhendetectedlater,or 3)thosethat areoverdiagnosedandwouldnothavecaused ahealth problem during a woman's lifetime and may result in harms from unnecessary treatment. PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Delaware SemanticType:[geoa] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:Lead SemanticType:[elii, hops] PreferredName:Categories SemanticType:[inpr] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:&lt;3 (qualifier value) SemanticType:[qnco] PreferredName:Better SemanticType:[qlco] PreferredName:Result SemanticType:[ftcn] PreferredName:Result SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Problem SemanticType:[fndg] PreferredName:Woman SemanticType:[popg] POS:IN POS:JJ POS:VB POS:, POS:NN POS:MD POS:CD POS:IN POS:DT POS:NN POS:: POS:CD POS:CD POS:NNS POS:IN POS:WDT POS:CD POS:DT POS:VBZ POS:TO POS:JJR POS:NN POS:, POS:CD POS:VBN POS:NNS POS:WDT POS:MD POS:CD POS:DT POS:NN POS:, POS:VB POS:VBD POS:NN POS:NN POS:CC POS:CD POS:NN POS:IN POS:VBD POS:NN POS:POS POS:NN POS:DT POS:NN POS:VB POS:IN POS:CC POS:MD POS:JJ POS:NN POS:NNS POS:IN POS:. 
[sentNum: 99]<Annotation Id="160959" Type="Sentence" StartNode="12668" EndNode="12815">Existing data do notallowforestimationoftheproportionof cancer that falls into each category; therefore, the bene.ts on health cannot be estimated. PreferredName:Falls SemanticType:[fndg] PreferredName:Categories SemanticType:[inpr] PreferredName:Data SemanticType:[idcn] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Estimated SemanticType:[qnco] PreferredName:MALL gene SemanticType:[gngm] PreferredName:Health SemanticType:[idcn] POS:NNS POS:VBP POS:VBG POS:WDT POS:VBZ POS:JJ POS:NN POS:NN POS:: POS:IN POS:DT POS:DT POS:NN POS:RB POS:, POS:IN POS:NN POS:. POS:NNS POS:VB POS:VBN POS:MD POS:RB POS:. 
[sentNum: 100]<Annotation Id="160956" Type="Sentence" StartNode="11945" EndNode="12075">Most of the additional cancer detected by these methods are inva­sive tumors rather than ductal carcinoma in situ (DCIS) (17, 18). PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Detection SemanticType:[topp] PreferredName:Most SemanticType:[qnco] PreferredName:Additional SemanticType:[ftcn] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:Methods aspects SemanticType:[inpr] PreferredName:Neoplasm SemanticType:[neop] POS:IN POS:DT POS:JJS POS:VBN POS:IN POS:JJ POS:NN POS:VBP POS:JJ POS:DT POS:NNS POS:IN POS:JJ POS:NNS POS:RB POS:FW POS:FW POS:NN POS:FW POS:CD POS:CD POS:NN POS:CD POS:NN POS:. POS:, POS:CD 
[sentNum: 101]<Annotation Id="160957" Type="Sentence" StartNode="12076" EndNode="12294">A short-term increase in the number of cancer cases detected does not allow for the conclusion that adjunctive screening reduces treatment-related mor­bidity or breast cancer deaths or improves women's quality of life. PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Woman SemanticType:[popg] PreferredName:moira protein, Drosophila SemanticType:[aapp, bacs] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Perceived quality of life SemanticType:[fndg] PreferredName:Short-term SemanticType:[tmco] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:allowing SemanticType:[socb] PreferredName:Conclusion SemanticType:[idcn] PreferredName:Detection SemanticType:[topp] PreferredName:Negation SemanticType:[ftcn] PreferredName:Therapeutic procedure SemanticType:[topp] PreferredName:Relationships SemanticType:[qlco] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:NN POS:IN POS:DT POS:JJ POS:IN POS:NN POS:DT POS:NN POS:VBZ POS:RB POS:NNS POS:VBD POS:DT POS:NN POS:VB POS:IN POS:NN POS:VBZ POS:IN POS:JJ POS:CC POS:NN POS:JJ POS:NN POS:CC POS:VBZ POS:NN POS:NNS POS:NN POS:IN POS:NNS POS:POS POS:NN POS:. 
[sentNum: 102]<Annotation Id="160962" Type="Sentence" StartNode="12917" EndNode="13042">Com­pared with mammography alone, adjunctive screening with ultrasonography or MRI seems to increase recall and biopsy rates. PreferredName:alone - group size SemanticType:[grpa] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Screening mammography SemanticType:[topp] PreferredName:To SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:Ultrasonography SemanticType:[diap] PreferredName:Magnetic Resonance Imaging SemanticType:[diap] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Biopsy SemanticType:[diap] POS:NN POS:RB POS:VBN POS:IN POS:NN POS:IN POS:, POS:JJ POS:NNP POS:VBZ POS:NN POS:CC POS:NN POS:CC POS:TO POS:VB POS:. POS:NN POS:NNS 
[sentNum: 103]<Annotation Id="160963" Type="Sentence" StartNode="13043" EndNode="13170">Data on the effects of DBT on recall and biopsy rates in women with dense breasts are too limited to draw conclusions (17, 18). PreferredName:Data SemanticType:[idcn] PreferredName:Recall:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Biopsy SemanticType:[diap] PreferredName:Effect SemanticType:[qlco] PreferredName:DBT gene SemanticType:[gngm] PreferredName:Dense breasts NOS SemanticType:[fndg] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Woman SemanticType:[popg] PreferredName:Conclusion SemanticType:[idcn] PreferredName:To SemanticType:[qlco] PreferredName:Drawings (art) SemanticType:[inpr] POS:NNS POS:NNS POS:IN POS:IN POS:DT POS:NN POS:CC POS:NNP POS:IN POS:IN POS:NNS POS:NN POS:NNS POS:NNS POS:VBP POS:IN POS:JJ POS:TO POS:VB POS:RB POS:JJ POS:CD POS:, POS:NNS POS:CD POS:. POS:CD POS:NN 
[sentNum: 104]<Annotation Id="160960" Type="Sentence" StartNode="12818" EndNode="12834">Potential Harms. PreferredName:Potential SemanticType:[qlco] POS:NNS POS:. POS:JJ 
[sentNum: 105]<Annotation Id="160961" Type="Sentence" StartNode="12835" EndNode="12916">Most positive adjunctive breast cancer screening test results are false positive. PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Most SemanticType:[qnco] PreferredName:Positive Laboratory Test Result SemanticType:[fndg] PreferredName:False Positive SemanticType:[lbtr] POS:JJ POS:NN POS:JJS POS:JJ POS:NN POS:NNS POS:NN POS:VBG POS:JJ POS:. POS:VBP POS:JJ 
[sentNum: 106]<Annotation Id="160966" Type="Sentence" StartNode="13246" EndNode="13502">At the present time, 24 states re­quire patient noti.cation of breast density status when mammography is performed; in some states, legisla­tion also includes language to be sent to women in­forming them that they should consider adjunctive screening (17). PreferredName:Present SemanticType:[qnco] PreferredName:Time SemanticType:[tmco] PreferredName:Patient status SemanticType:[fndg] PreferredName:Notuss SemanticType:[orch, phsu] PreferredName:Geographic state SemanticType:[geoa] PreferredName:Respiratory Domain SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Performed SemanticType:[ftcn] PreferredName:Cations SemanticType:[chvs] PreferredName:Breast Density SemanticType:[clna] PreferredName:Languages SemanticType:[lang] PreferredName:Send (transmission) SemanticType:[ftcn] PreferredName:Geographic state SemanticType:[geoa] PreferredName:include - SetOperator SemanticType:[idcn] PreferredName:consider SemanticType:[idcn] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Formation SemanticType:[ftcn] PreferredName:Aspects of disease screening SemanticType:[ftcn] POS:JJ POS:NN POS:IN POS:DT POS:NNS POS:JJ POS:, POS:CD POS:. POS:NN POS:NN POS:NNS POS:NN POS:NN POS:IN POS:NN POS:VBZ POS:VBN POS:WRB POS:NN POS:DT POS:NNS POS:: POS:IN POS:RB POS:VBZ POS:, POS:NN POS:VB POS:VBN POS:NN POS:TO POS:VBG POS:PRP POS:TO POS:NNS POS:MD POS:VB POS:IN POS:PRP POS:NN POS:CD POS:JJ POS:NN POS:NN POS:. 
[sentNum: 107]<Annotation Id="160967" Type="Sentence" StartNode="13503" EndNode="13663">No clinical practice guidelines explicitly recommend adjunctive screening in women identi.ed tohavedensebreastson anotherwisenegative screen­ing mammogram (17). PreferredName:Recommendation SemanticType:[idcn] PreferredName:Adjunctive Orthodontic Procedure SemanticType:[topp] PreferredName:Clinical Practice Guideline SemanticType:[inpr] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Woman SemanticType:[popg] PreferredName:Endocrine System Findings Domain SemanticType:[idcn] POS:DT POS:JJ POS:RB POS:VB POS:NN POS:NNS POS:IN POS:NNS POS:JJ POS:NN POS:VBD POS:NN POS:NNS POS:. POS:NN POS:NN POS:JJ POS:VBG POS:. POS:CD POS:NN 
[sentNum: 108]<Annotation Id="160964" Type="Sentence" StartNode="13171" EndNode="13225">The effects of DBT on overdiagnosis rates are unknown. PreferredName:Effect SemanticType:[qlco] PreferredName:Rating (action) SemanticType:[acty] PreferredName:Unknown SemanticType:[qlco] PreferredName:DBT gene SemanticType:[gngm] PreferredName:overdiagnosis SemanticType:[fndg] POS:DT POS:NNP POS:IN POS:NNS POS:IN POS:VBP POS:JJ POS:NN POS:NNS POS:. 
[sentNum: 109]<Annotation Id="160965" Type="Sentence" StartNode="13228" EndNode="13245">Current Practice. PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Practice Experience SemanticType:[menp] POS:NN POS:. POS:JJ 
[sentNum: 110]<Annotation Id="160970" Type="Sentence" StartNode="13724" EndNode="13889">It is an independent risk factor for developing (but not dying of) breast cancer, and it reduces mammography's abil­ity to .nd and accurately identify breast cancer. PreferredName:risk factors SemanticType:[qnco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Independence SemanticType:[idcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Dying Process SemanticType:[orgf] PreferredName:Malignant neoplasm of breast SemanticType:[neop] POS:PRP POS:JJ POS:NN POS:VBZ POS:DT POS:VBG POS:NN POS:NN POS:IN POS:VBG POS:IN POS:CC POS:RB POS:NN POS:, POS:JJ POS:NN POS:VBZ POS:NN POS:CC POS:PRP POS:TO POS:. POS:POS POS:NN POS:RB POS:VB POS:NN POS:CC POS:. POS:NN POS:NN 
[sentNum: 111]<Annotation Id="160971" Type="Sentence" StartNode="13890" EndNode="14074">Many women will move between &#x201c;dense&#x201d; and &#x201c;nondense&#x201d; breast classi.cations with sequential screening mam­mograms, and these reclassi.cations are not primarily due to physiologic causes. PreferredName:Dense SemanticType:[qlco] PreferredName:And SemanticType:[idcn] PreferredName:Woman SemanticType:[popg] PreferredName:Moved to SemanticType:[ftcn] PreferredName:Sequential - Sequence/Results Flag SemanticType:[idcn] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Cations SemanticType:[chvs] PreferredName:Negation SemanticType:[ftcn] PreferredName:Due to SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:Cations SemanticType:[chvs] PreferredName:Physiological SemanticType:[ftcn] PreferredName:Etiology SemanticType:[ftcn] POS:JJ POS:VB POS:IN POS:NNS POS:MD POS:NN POS:CC POS:CD POS:JJ POS:NN POS:NN POS:NN POS:JJ POS:NNS POS:IN POS:NNS POS:. POS:NNS POS:, POS:JJ POS:NN POS:NNS POS:. POS:CC POS:DT POS:RB POS:RB POS:NNS POS:VBP POS:JJ POS:NNS POS:JJ POS:TO POS:. 
[sentNum: 112]<Annotation Id="160968" Type="Sentence" StartNode="13670" EndNode="13680">Assessment PreferredName:Evaluation procedure SemanticType:[hlca] POS:NNP 
[sentNum: 113]<Annotation Id="160969" Type="Sentence" StartNode="13683" EndNode="13723">Increased breast density is very common. PreferredName:Breast Density SemanticType:[clna] PreferredName:Very SemanticType:[qlco] PreferredName:Increase SemanticType:[ftcn] PreferredName:shared attribute SemanticType:[ftcn] POS:NN POS:VBZ POS:VBN POS:NN POS:. POS:RB POS:JJ 
[sentNum: 114]<Annotation Id="160974" Type="Sentence" StartNode="14471" EndNode="14501">Other Approaches to Prevention PreferredName:Other preventive procedure SemanticType:[topp] PreferredName:Approach SemanticType:[spco] POS:TO POS:NNP POS:JJ POS:NNS 
[sentNum: 115]<Annotation Id="160975" Type="Sentence" StartNode="14504" EndNode="14740">The USPSTF has made recommendations about the use of medications to reduce women's risk for breast cancer, as well as risk assessment, genetic coun­seling, and genetic testing for BRCA1-or BRCA2­related cancer (including breast cancer). PreferredName:Advice SemanticType:[hlca] PreferredName:Use of SemanticType:[ftcn] PreferredName:Make - Instruction Imperative SemanticType:[ftcn] PreferredName:Risk SemanticType:[qlco] PreferredName:Risk Assessment SemanticType:[hlca] PreferredName:Medications:-:Point in time:^Patient:- SemanticType:[clna] PreferredName:Female Breast Carcinoma SemanticType:[neop] PreferredName:Genetic screening method SemanticType:[lbpr] PreferredName:BRCA2 gene SemanticType:[gngm] PreferredName:Genetic SemanticType:[ftcn] PreferredName:SELE gene SemanticType:[gngm] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Relationships SemanticType:[qlco] PreferredName:Primary malignant neoplasm SemanticType:[neop] POS:VBZ POS:VBN POS:DT POS:NNP POS:DT POS:NN POS:NNS POS:IN POS:TO POS:VB POS:IN POS:NNS POS:NN POS:IN POS:NNS POS:POS POS:, POS:RB POS:NN POS:NN POS:NN POS:NN POS:RB POS:IN POS:NN POS:, POS:, POS:JJ POS:NN POS:IN POS:CC POS:JJ POS:: POS:CC POS:NNP POS:LS POS:CD POS:JJ POS:NNP POS:CD POS:VBG POS:NN POS:NN POS:NN POS:. POS:NN POS:NN 
[sentNum: 116]<Annotation Id="160972" Type="Sentence" StartNode="14075" EndNode="14218">More evidence is needed to better understand how the frequency of screening might affect important health outcomes in women with dense breasts. PreferredName:More SemanticType:[ftcn] PreferredName:Evidence of SemanticType:[ftcn] PreferredName:Better SemanticType:[qlco] PreferredName:Comprehension SemanticType:[menp] PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Affect (mental function) SemanticType:[menp] PreferredName:Health Outcomes SemanticType:[inpr] PreferredName:With frequency SemanticType:[qnco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Dense breasts NOS SemanticType:[fndg] POS:NN POS:VBZ POS:RBR POS:RBR POS:VB POS:VBN POS:TO POS:NN POS:IN POS:WRB POS:DT POS:VB POS:JJ POS:NN POS:MD POS:IN POS:NNS POS:NN POS:NNS POS:NNS POS:. POS:IN POS:JJ 
[sentNum: 117]<Annotation Id="160973" Type="Sentence" StartNode="14219" EndNode="14464">Overall, many important questions re­main about the potential role of breast density in indi­vidualizing screening approaches, and the current evi­dence isinsuf.cienttorecommend aspeci.cscreening strategy for women with increased breast density. PreferredName:Overall Publication Type SemanticType:[inpr] PreferredName:Numerous SemanticType:[qnco] PreferredName:Main SemanticType:[qlco] PreferredName:Potential SemanticType:[qlco] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:Respiratory Domain SemanticType:[idcn] PreferredName:indicine-N-oxide SemanticType:[orch, phsu] PreferredName:Disease Screening SemanticType:[diap] PreferredName:Social Role SemanticType:[socb] PreferredName:Breast Density SemanticType:[clna] PreferredName:WLS gene SemanticType:[gngm] PreferredName:strategy SemanticType:[menp] PreferredName:Approach SemanticType:[spco] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Woman SemanticType:[popg] PreferredName:Decreased translucency SemanticType:[fndg] POS:JJ POS:JJ POS:RB POS:, POS:IN POS:DT POS:NNS POS:VBG POS:IN POS:NN POS:JJ POS:NN POS:VBG POS:JJ POS:NN POS:IN POS:CC POS:DT POS:NNS POS:, POS:NN POS:. POS:JJ POS:NN POS:. POS:VBG POS:NN POS:NNS POS:NNS POS:IN POS:NN POS:IN POS:NN POS:. POS:VBN POS:NN 
[sentNum: 118]<Annotation Id="160978" Type="Sentence" StartNode="14869" EndNode="14892">Research Needs and Gaps PreferredName:research needs SemanticType:[resa] POS:NNP POS:NNS POS:CC POS:NNS 
[sentNum: 119]<Annotation Id="160979" Type="Sentence" StartNode="14895" EndNode="15069">Trial data are too limited to directly inform the question of what the best screening strategy is for women or how clinicians can best tailor that strategy to the individual. PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Data SemanticType:[idcn] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:inform SemanticType:[idcn] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:To SemanticType:[qlco] PreferredName:Disease Screening SemanticType:[diap] PreferredName:strategy SemanticType:[menp] PreferredName:Question (inquiry) SemanticType:[inpr] PreferredName:best (quality) SemanticType:[qlco] PreferredName:best (quality) SemanticType:[qlco] PreferredName:Tailor SemanticType:[prog] PreferredName:Woman SemanticType:[popg] PreferredName:Clinician SemanticType:[prog] PreferredName:strategy SemanticType:[menp] PreferredName:Persons SemanticType:[popg] POS:NN POS:NNS POS:JJ POS:TO POS:VBP POS:RB POS:DT POS:NN POS:RB POS:VB POS:DT POS:JJS POS:IN POS:WP POS:VBZ POS:IN POS:NN POS:NN POS:WRB POS:NNS POS:NNS POS:CC POS:NN POS:WDT POS:MD POS:JJS POS:DT POS:NN POS:NN POS:TO POS:. 
[sentNum: 120]<Annotation Id="160976" Type="Sentence" StartNode="14741" EndNode="14841">These recom­mendations are available on the USPSTF Web site (www.uspreventiveservicestaskforce.org). PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:Availability of SemanticType:[ftcn] PreferredName:Web Site SemanticType:[inpr] POS:DT POS:JJ POS:IN POS:NNS POS:VBP POS:NN POS:NN POS:DT POS:NNP POS:. POS:NN POS:CD POS:NN POS:NN POS:. POS:. POS:NN 
[sentNum: 121]<Annotation Id="160977" Type="Sentence" StartNode="14844" EndNode="14864">OTHER CONSIDERATIONS PreferredName:consideration SemanticType:[fndg] POS:JJ POS:NNS 
[sentNum: 122]<Annotation Id="160982" Type="Sentence" StartNode="15496" EndNode="15599">Current estimates of the magnitude of overdiag­nosis associated with mammography screening vary widely. PreferredName:Current (present time) SemanticType:[tmco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Magnitude SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] POS:NNS POS:IN POS:JJ POS:IN POS:NN POS:DT POS:NN POS:NN POS:NN POS:VBN POS:IN POS:. POS:VBP POS:RB 
[sentNum: 123]<Annotation Id="160983" Type="Sentence" StartNode="15600" EndNode="15827">Researchers in the .eld must work together to critically evaluate and ultimately agree on uniform def­initions and standards to optimally measure and moni­tor overdiagnosis and overtreatment in breast cancer screening programs. PreferredName:Research Personnel SemanticType:[prog] PreferredName:Evaluation SemanticType:[ftcn] PreferredName:Agree SemanticType:[inpr] PreferredName:Work SemanticType:[ocac] PreferredName:Together SemanticType:[qlco] PreferredName:standards characteristics SemanticType:[inpr] PreferredName:Measurement SemanticType:[ftcn] PreferredName:Uniform - quality SemanticType:[qlco] PreferredName:butyl phosphorotrithioate SemanticType:[hops, opco] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Programs - Publication Format SemanticType:[inpr] PreferredName:Toremifene SemanticType:[orch, phsu] PreferredName:overdiagnosis SemanticType:[fndg] POS:NNS POS:. POS:NN POS:IN POS:DT POS:RB POS:TO POS:MD POS:VB POS:CC POS:RB POS:RB POS:VB POS:JJ POS:NNS POS:VBP POS:IN POS:TO POS:RB POS:CC POS:NNS POS:VB POS:NN POS:VB POS:CC POS:IN POS:NN POS:CC POS:NN POS:NNS POS:. POS:NN POS:NN 
[sentNum: 124]<Annotation Id="160980" Type="Sentence" StartNode="15072" EndNode="15284">Overdiagnosis and resulting overtreatment of breast cancer that would otherwise not have become a threat to a woman's health during her lifetime is the most important harm associated with breast cancer screening. PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Due to SemanticType:[ftcn] PreferredName:threat SemanticType:[idcn] PreferredName:Women's Health SemanticType:[bmod] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Negation SemanticType:[ftcn] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Most SemanticType:[qnco] PreferredName:Associated with SemanticType:[qlco] POS:CC POS:VBG POS:NNP POS:NN POS:NN POS:NN POS:IN POS:RB POS:RB POS:WDT POS:MD POS:DT POS:NN POS:VB POS:VBN POS:NN POS:POS POS:TO POS:DT POS:PRP$ POS:NN POS:NN POS:IN POS:RBS POS:JJ POS:VBZ POS:DT POS:IN POS:NN POS:NN POS:VBN POS:. POS:NN POS:NN 
[sentNum: 125]<Annotation Id="160981" Type="Sentence" StartNode="15285" EndNode="15495">Because it is impossible to determine for any individual patient whether a diagnosed cancer will or will not progress, measurements of overdiagnosis are not straightforward but rather are indirectly quanti­.ed. PreferredName:Persons SemanticType:[popg] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Negation SemanticType:[ftcn] PreferredName:Patients SemanticType:[podg] PreferredName:Diagnosis SemanticType:[fndg] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Progress SemanticType:[ftcn] PreferredName:Measurement SemanticType:[ftcn] PreferredName:Straightforward SemanticType:[qlco] PreferredName:Endocrine System Findings Domain SemanticType:[idcn] POS:IN POS:JJ POS:TO POS:PRP POS:VBZ POS:DT POS:JJ POS:VB POS:IN POS:DT POS:VBN POS:NN POS:IN POS:CC POS:MD POS:NN POS:MD POS:, POS:NNS POS:RB POS:VB POS:VBP POS:RB POS:IN POS:NN POS:RB POS:VBP POS:JJ POS:CC POS:. POS:VBN POS:RB POS:RB POS:. 
[sentNum: 126]<Annotation Id="160986" Type="Sentence" StartNode="16029" EndNode="16036">164 No. POS:CD POS:DT POS:. 
[sentNum: 127]<Annotation Id="160987" Type="Sentence" StartNode="16037" EndNode="16072">4 &#x2022; 16 February 2016 www.annals.org PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] POS:CD POS:CD POS:CD POS:NN POS:CD POS:NNP POS:. POS:NN POS:. POS:NN 
[sentNum: 128]<Annotation Id="160984" Type="Sentence" StartNode="15830" EndNode="15988">In addition, research is critically needed to identify ways to reduce the occurrence of overdiagnosis and subsequent overtreatment associated with breast can­PreferredName:Needs SemanticType:[qlco] PreferredName:To SemanticType:[qlco] PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:Research Activities SemanticType:[resa] PreferredName:Following SemanticType:[tmco] PreferredName:Associated with SemanticType:[qlco] PreferredName:Occurrence SemanticType:[tmco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Entire breast SemanticType:[bpoc] POS:, POS:NN POS:IN POS:NN POS:VBN POS:TO POS:VBZ POS:RB POS:TO POS:VB POS:VB POS:NNS POS:IN POS:NN POS:DT POS:NN POS:NN POS:VBN POS:CC POS:JJ POS:NN POS:IN POS:NN 
[sentNum: 129]<Annotation Id="160985" Type="Sentence" StartNode="15990" EndNode="16028">286 Annals of Internal Medicine &#x2022; Vol. PreferredName:% volume (qualifier value) SemanticType:[qlco] PreferredName:Internal medicine physicians SemanticType:[inpr] POS:CD POS:JJ POS:NN POS:NNS POS:IN POS:. POS:NN POS:NN 
[sentNum: 130]<Annotation Id="160990" Type="Sentence" StartNode="16207" EndNode="16245">Harms of Early Detection and Treatment PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:First-Line Therapy SemanticType:[topp] POS:JJ POS:NN POS:NNS POS:IN POS:CC POS:NN 
[sentNum: 131]<Annotation Id="160991" Type="Sentence" StartNode="16248" EndNode="16295">Primary Screening With Conventional Mammography PreferredName:Screening mammography SemanticType:[topp] PreferredName:classical example SemanticType:[qlco] POS:JJ POS:VBG POS:NN POS:IN POS:JJ 
[sentNum: 132]<Annotation Id="160988" Type="Sentence" StartNode="16081" EndNode="16127">CLINICAL GUIDELINE Screening for Breast Cancer PreferredName:Guidelines SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Clinical SemanticType:[qlco] POS:VBG POS:IN POS:JJ POS:NN POS:NN POS:NN 
[sentNum: 133]<Annotation Id="160989" Type="Sentence" StartNode="16130" EndNode="16202">breasts on breast cancer rates, quality of life, or mortal­ity (17, 18). PreferredName:Quality of life SemanticType:[idcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Rate SemanticType:[qnco] POS:NNS POS:IN POS:NNS POS:, POS:NN POS:NN POS:NN POS:, POS:NN POS:IN POS:CD POS:CD POS:CC POS:NN POS:NN POS:. POS:, POS:CD 
[sentNum: 134]<Annotation Id="160994" Type="Sentence" StartNode="16498" EndNode="16766">Stud­ies show a fairly consistent association between a false-positive screening mammogram and increased breast cancer&#x2013;speci.c distress, anxiety, and apprehension, particularly in women who have an associated proce­dure, such as .ne-needle aspiration or breast biopsy. PreferredName:Show SemanticType:[inpr] PreferredName:Consistent with SemanticType:[idcn] PreferredName:TBPL1 wt Allele SemanticType:[gngm] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Increase SemanticType:[ftcn] PreferredName:Mental association SemanticType:[menp] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Anxiety SemanticType:[menp] PreferredName:apprehension SemanticType:[fndg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Distress SemanticType:[menp] PreferredName:ELANE wt Allele SemanticType:[gngm] PreferredName:Aspiration needles SemanticType:[medd] PreferredName:Woman SemanticType:[popg] PreferredName:Associated with SemanticType:[qlco] PreferredName:Biopsy of breast SemanticType:[diap] POS:NNS POS:RB POS:JJ POS:VBP POS:DT POS:DT POS:JJ POS:NN POS:IN POS:CC POS:VBD POS:NN POS:NN POS:. POS:LS POS:NN POS:NNS POS:NN POS:, POS:NN POS:, POS:, POS:RB POS:CC POS:NN POS:WP POS:VBP POS:IN POS:NNS POS:NN POS:, POS:DT POS:VBN POS:. POS:JJ POS:JJ POS:IN POS:NN POS:NN POS:NN POS:CC POS:. 
[sentNum: 135]<Annotation Id="160995" Type="Sentence" StartNode="16767" EndNode="16821">These effects improve over time for most women (2, 4). PreferredName:Time SemanticType:[tmco] PreferredName:Woman SemanticType:[popg] PreferredName:Effect SemanticType:[qlco] PreferredName:Integer +2 SemanticType:[qnco] POS:NNS POS:VBP POS:DT POS:IN POS:JJS POS:IN POS:NN POS:CD POS:, POS:NNS POS:VBP POS:. POS:CD POS:NN 
[sentNum: 136]<Annotation Id="160992" Type="Sentence" StartNode="16298" EndNode="16348">Screening mammography has several potential harms. PreferredName:Numerous SemanticType:[qnco] PreferredName:Potential SemanticType:[qlco] POS:VBG POS:JJ POS:JJ POS:NN POS:VBZ POS:NNS POS:. 
[sentNum: 137]<Annotation Id="160993" Type="Sentence" StartNode="16349" EndNode="16497">The most common is a false-positive result, which can lead to psychological harms, as well as addi­tional testing and invasive follow-up procedures. PreferredName:Common (qualifier value) SemanticType:[qnco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Most SemanticType:[qnco] PreferredName:Testing SemanticType:[ftcn] PreferredName:Surgical aspects SemanticType:[ftcn] PreferredName:Lead SemanticType:[elii, hops] PreferredName:Psychiatric problem SemanticType:[mobd] PreferredName:Follow-Up Report SemanticType:[inpr] POS:DT POS:RBS POS:DT POS:JJ POS:JJ POS:VBZ POS:WDT POS:MD POS:NN POS:, POS:JJ POS:NNS POS:VB POS:TO POS:RB POS:IN POS:, POS:RB POS:CC POS:JJ POS:JJ POS:NN POS:. POS:NN POS:NNS 
[sentNum: 138]<Annotation Id="160998" Type="Sentence" StartNode="17300" EndNode="17482">Overdiagnosis occurs when the breast tumor does not progress or when the woman dies of a competing cause of death before the breast cancer advances to the point of causing symp­toms. PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:Progress SemanticType:[ftcn] PreferredName:Occurrence SemanticType:[tmco] PreferredName:Mammary Neoplasms SemanticType:[neop] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Advance SemanticType:[medd] PreferredName:Woman SemanticType:[popg] PreferredName:Cause of Death SemanticType:[fndg] PreferredName:PRPF6 gene SemanticType:[gngm] PreferredName:point - UnitsOfMeasure SemanticType:[qnco] PreferredName:Causing SemanticType:[ftcn] POS:WRB POS:DT POS:NN POS:VBZ POS:VBZ POS:RB POS:NN POS:NN POS:WRB POS:DT POS:VB POS:CC POS:IN POS:DT POS:NN POS:VBZ POS:IN POS:NN POS:VBG POS:NN POS:NN POS:NN POS:IN POS:DT POS:DT POS:NN POS:NNS POS:TO POS:NNS POS:. POS:IN POS:VBG 
[sentNum: 139]<Annotation Id="160999" Type="Sentence" StartNode="17483" EndNode="17529">Overdiagnosis is not the same as misdiagnosis. PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Misdiagnosis SemanticType:[fndg] PreferredName:Negation SemanticType:[ftcn] PreferredName:SAME AS SemanticType:[clas] POS:RB POS:DT POS:NNP POS:VBZ POS:NN POS:. POS:JJ POS:IN 
[sentNum: 140]<Annotation Id="160996" Type="Sentence" StartNode="16822" EndNode="17076">Table 5 summarizes BCSC data on the cumulative probability of a woman (at varying starting ages and intervals) receiving at least 1 false-positive mammo­gram or a recommendation for what turns out to be a false-positive biopsy over a 10-year period (39). PreferredName:Breast Cancer Surveillance Consortium SemanticType:[prog] PreferredName:Data SemanticType:[idcn] PreferredName:Table - furniture SemanticType:[mnob] PreferredName:Woman SemanticType:[popg] PreferredName:Beginning SemanticType:[tmco] PreferredName:Cumulative SemanticType:[qlco] PreferredName:Probability SemanticType:[qnco] PreferredName:Receive SemanticType:[qlco] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Age SemanticType:[orga] PreferredName:Interval SemanticType:[tmco] PreferredName:Does turn (finding) SemanticType:[fndg] PreferredName:Out (direction) SemanticType:[spco] PreferredName:gram SemanticType:[qnco] PreferredName:Recommendation SemanticType:[idcn] PreferredName:Biopsy SemanticType:[diap] PreferredName:per year SemanticType:[tmco] PreferredName:antineoplaston A10 SemanticType:[orch, phsu] PreferredName:False Positive SemanticType:[lbtr] PreferredName:Period (temporal qualifier) SemanticType:[tmco] POS:NNP POS:NNP POS:NNS POS:CD POS:VBZ POS:JJ POS:NN POS:IN POS:DT POS:NN POS:CD POS:IN POS:DT POS:VBG POS:NNS POS:IN POS:VBG POS:VBP POS:VBG POS:CC POS:NNS POS:CD POS:JJ POS:IN POS:JJS POS:DT POS:NN POS:NN POS:CC POS:VBZ POS:RP POS:IN POS:WP POS:DT POS:JJ POS:TO POS:VB POS:DT POS:CD POS:NN POS:IN POS:NN POS:CD POS:: POS:NN POS:. POS:CD POS:NN 
[sentNum: 141]<Annotation Id="160997" Type="Sentence" StartNode="17079" EndNode="17299">The most serious harm of screening mammogra­phyisthediagnosisandtreatmentofbreast cancerthat would never have become a threat to a woman's health, or even apparent, during her lifetime (overdiag­nosis and overtreatment). PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Never (frequency) SemanticType:[tmco] PreferredName:Serious SemanticType:[qlco] PreferredName:apparent SemanticType:[idcn] PreferredName:threat SemanticType:[idcn] PreferredName:Women's Health SemanticType:[bmod] POS:DT POS:NN POS:IN POS:RBS POS:JJ POS:NN POS:MD POS:VBG POS:JJ POS:VBN POS:DT POS:RB POS:VB POS:DT POS:NN POS:NN POS:TO POS:, POS:CC POS:POS POS:NN POS:, POS:IN POS:RB POS:JJ POS:CD POS:NN POS:PRP$ POS:NN POS:NN POS:. POS:CC POS:NN 
[sentNum: 142]<Annotation Id="161002" Type="Sentence" StartNode="18053" EndNode="18468">Researchers have used multiple data sources to attempt to quantify overdiagnosis rates associated with mammography screening, including RCTs, pathology and imaging studies, ecologic and cohort studies, and decision modeling.Toadditionallycomplicatematters,thereisa lack of consensus concerning the optimal method for calculating the magnitude of overdiagnosis, and inves­tigators differ in their approaches (6, 40). PreferredName:Used by SemanticType:[fndg] PreferredName:Numerous SemanticType:[qnco] PreferredName:Research Personnel SemanticType:[prog] PreferredName:To SemanticType:[qlco] PreferredName:Quantitation SemanticType:[qnco] PreferredName:Data Sources SemanticType:[qnco] PreferredName:Attempt SemanticType:[evnt] PreferredName:Associated with SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Rate SemanticType:[qnco] PreferredName:Image Study SemanticType:[diap] PreferredName:Ecology SemanticType:[ocdi] PreferredName:Including (qualifier) SemanticType:[ftcn] PreferredName:Pathological aspects SemanticType:[ftcn] PreferredName:Lacking SemanticType:[qlco] PreferredName:Consensus SemanticType:[socb] PreferredName:Cohort Studies SemanticType:[qnco] PreferredName:Decision Modeling SemanticType:[inpr] PreferredName:Methods SemanticType:[inpr] PreferredName:Calculation SemanticType:[acty] PreferredName:Concern SemanticType:[idcn] PreferredName:Optimum SemanticType:[qlco] PreferredName:Approach SemanticType:[spco] PreferredName:/40 SemanticType:[tmco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] POS:NNS POS:VBP POS:NNS POS:NNS POS:VBN POS:JJ POS:TO POS:VB POS:TO POS:VB POS:VBN POS:IN POS:NN POS:NNS POS:, POS:VBG POS:NN POS:NN POS:NN POS:CC POS:NNS POS:, POS:, POS:JJ POS:NN POS:NNS POS:NNS POS:, POS:CC POS:NN POS:NN POS:. POS:CC POS:NN POS:RB POS:NN POS:NNPS POS:, POS:VBG POS:DT POS:IN POS:NN POS:IN POS:VBG POS:JJ POS:NN POS:IN POS:NN POS:DT POS:NN POS:NNS POS:VBP POS:, POS:CC POS:NNS POS:VBP POS:IN POS:PRP$ POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 143]<Annotation Id="161003" Type="Sentence" StartNode="18469" EndNode="18565">This has re­sulted in a wide range of estimates in the available lit­erature (0% to 54%) (2, 4). PreferredName:Sample Range SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Respiratory Domain SemanticType:[idcn] PreferredName:Widening SemanticType:[spco] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Availability of SemanticType:[ftcn] PreferredName:TNFRSF10C gene SemanticType:[gngm] POS:VBZ POS:VBN POS:DT POS:JJ POS:NN POS:IN POS:DT POS:IN POS:DT POS:IN POS:NNS POS:NN POS:CD POS:JJ POS:JJ POS:CD POS:NN POS:NN POS:TO POS:CD POS:, POS:CD POS:NN POS:. POS:CD POS:NN 
[sentNum: 144]<Annotation Id="161000" Type="Sentence" StartNode="17530" EndNode="17811">Misdiagnosis is when a cancer is incorrectly classi.ed by an individual pathologist; overdiagnosis, on the other hand, happens when there is general agreement by pathologists on how to classify the cancer, but the tumor does not go on to behave as expected based on its appearance. PreferredName:Misdiagnosis SemanticType:[fndg] PreferredName:Individual SemanticType:[humn] PreferredName:Medical pathologist SemanticType:[prog] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Endocrine System Findings Domain SemanticType:[idcn] PreferredName:Occur (action) SemanticType:[acty] PreferredName:General pathologist SemanticType:[prog] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Hand SemanticType:[bpoc] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Agreement SemanticType:[socb] PreferredName:Classification SemanticType:[clas] PreferredName:Expected SemanticType:[idcn] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:GORAB gene SemanticType:[gngm] PreferredName:Personal appearance SemanticType:[orga] POS:WRB POS:DT POS:NNP POS:VBZ POS:RB POS:NNS POS:NN POS:VBZ POS:IN POS:DT POS:. POS:VBN POS:: POS:NN POS:JJ POS:NN POS:DT POS:JJ POS:, POS:IN POS:VBZ POS:WRB POS:NN POS:, POS:JJ POS:NN POS:EX POS:VBZ POS:IN POS:WRB POS:IN POS:NNS POS:DT POS:NN POS:TO POS:VB POS:DT POS:NN POS:, POS:CC POS:VB POS:IN POS:VBZ POS:RB POS:IN POS:VBN POS:TO POS:VB POS:PRP$ POS:NN POS:VBN POS:IN POS:. 
[sentNum: 145]<Annotation Id="161001" Type="Sentence" StartNode="17812" EndNode="18052">It is not possible to directly observe for any individual woman whether she has or does not have an overdiagnosed tumor; it is only possible to in­directly estimate the frequency of overdiagnosis that may occur across a screened population. PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Negation SemanticType:[ftcn] PreferredName:Negation SemanticType:[ftcn] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Individual SemanticType:[humn] PreferredName:Woman SemanticType:[popg] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Singular SemanticType:[qnco] PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Occurrence SemanticType:[tmco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Frequencies (time pattern) SemanticType:[tmco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Population Group SemanticType:[popg] POS:VBZ POS:RB POS:PRP POS:RB POS:VB POS:JJ POS:TO POS:JJ POS:NN POS:IN POS:DT POS:VBZ POS:CC POS:IN POS:PRP POS:VB POS:DT POS:VBZ POS:RB POS:: POS:PRP POS:JJ POS:NN POS:JJ POS:TO POS:VBZ POS:RB POS:DT POS:NN POS:RB POS:VB POS:WDT POS:MD POS:IN POS:NN POS:DT POS:VBN POS:VB POS:IN POS:NN POS:. 
[sentNum: 146]<Annotation Id="161006" Type="Sentence" StartNode="19487" EndNode="19842">CISNET deci­sion models also investigated the degree of overdiag­nosis likely to result from a screening mammography program.The6decisionmodelsreportedawiderange of estimates of the magnitude of overdiagnosis associ­ated with screening mammography (1.4% to 24.9% of invasive cancer and 30.5% to 84.5% of DCIS, depend­ing on the screening strategy) (7, 8). PreferredName:Deci SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] PreferredName:Cancer Intervention and Surveillance Modeling Network SemanticType:[hcro] PreferredName:Probably SemanticType:[idcn] PreferredName:Growth Inhibition Screening Result SemanticType:[cnce] PreferredName:Investigates SemanticType:[ftcn] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Estimated SemanticType:[qnco] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:Mammography SemanticType:[diap] PreferredName:Program SemanticType:[phsu] PreferredName:1/24 SemanticType:[fndg] PreferredName:Invasive Malignant Neoplasm SemanticType:[neop] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:strategy SemanticType:[menp] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:depend SemanticType:[medd] POS:NN POS:NNS POS:NNP POS:DT POS:NN POS:RB POS:VBD POS:JJ POS:TO POS:IN POS:NN POS:DT POS:NN POS:VB POS:IN POS:. POS:DT POS:NN POS:NN POS:IN POS:NNS POS:CD POS:NN POS:NN POS:IN POS:IN POS:DT POS:IN POS:JJ POS:NN POS:VBN POS:CD POS:. POS:NN POS:NN POS:TO POS:CD POS:CD POS:NN POS:NN POS:IN POS:. POS:CD POS:CC POS:CD POS:JJ POS:NN POS:NN POS:TO POS:. POS:CD POS:CD POS:NN POS:CD POS:. POS:, POS:VBG POS:IN POS:NNP POS:NN POS:NN POS:IN POS:DT POS:CD POS:, POS:CD POS:NN POS:. POS:CD POS:NN 
[sentNum: 147]<Annotation Id="161007" Type="Sentence" StartNode="19843" EndNode="20006">Assumptions in several of the models may have increased the likeli­hood of underestimating the true burden of overdiag­nosis associated with screening mammography. PreferredName:hoods SemanticType:[medd] PreferredName:True SemanticType:[qlco] PreferredName:Model SemanticType:[inpr] PreferredName:Increase SemanticType:[ftcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Burden SemanticType:[idcn] PreferredName:Associated with SemanticType:[qlco] POS:NNS POS:IN POS:DT POS:IN POS:JJ POS:VB POS:VBN POS:NNS POS:MD POS:IN POS:VBG POS:DT POS:NN POS:NN POS:IN POS:DT POS:JJ POS:IN POS:NN POS:NN POS:VBN POS:NN POS:. 
[sentNum: 148]<Annotation Id="161004" Type="Sentence" StartNode="18568" EndNode="19180">Of theavailable clinical trials, 3RCTs inwhich there was no mammography screening of the control groups attheendofthestudy(Malmo¨ MammographicScreen­ing Trial I and the Canadian National Breast Screening Study 1 and 2) provided the least-biased estimates, as they had the advantage of having comparable groups at baseline, adequate follow-up beyond the screening period to distinguish between earlier diagnosis and overdiagnosis, and clear distinction between which groupsreceivedscreeningandwhichdidnot(ifscreen­ing was also provided to the control group, then over­diagnosiscouldalso occurinthispopulation)(6).ThesePreferredName:Clinical Trials SemanticType:[resa] PreferredName:Control Groups SemanticType:[grup] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:no SemanticType:[idcn] PreferredName:Screening mammography SemanticType:[topp] PreferredName:National citizen SemanticType:[inpr] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Iodides SemanticType:[inch] PreferredName:CANADIAN SemanticType:[fndg] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Less Than SemanticType:[inpr] PreferredName:Screening Study SemanticType:[resa] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Population Group SemanticType:[popg] PreferredName:Baseline SemanticType:[qnco] PreferredName:Biases SemanticType:[idcn] PreferredName:Estimated SemanticType:[qnco] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Sufficient SemanticType:[qlco] PreferredName:Follow-Up Report SemanticType:[inpr] PreferredName:Clear SemanticType:[qlco] PreferredName:Providing (action) SemanticType:[acty] PreferredName:Early Diagnosis SemanticType:[diap] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Control Groups SemanticType:[grup] PreferredName:Then SemanticType:[tmco] POS:IN POS:NNS POS:, POS:JJ POS:JJ POS:VBP POS:EX POS:CD POS:NNS POS:NN POS:NN POS:VBD POS:DT POS:NN POS:NNS POS:IN POS:DT POS:NNP POS:CD POS:JJ POS:CD POS:NN POS:CC POS:VBG POS:NN POS:NNP POS:NN POS:DT POS:NNP POS:CD POS:CC POS:NN POS:NN POS:VBD POS:DT POS:CD POS:CD POS:, POS:IN POS:JJ POS:NNS POS:DT POS:NN POS:PRP POS:VBD POS:JJ POS:NNS POS:IN POS:VBG POS:, POS:JJ POS:IN POS:NN POS:DT POS:JJ POS:NN POS:IN POS:VB POS:IN POS:NN POS:TO POS:CC POS:NN POS:JJR POS:NN POS:JJ POS:NN POS:, POS:CC POS:NN POS:CD POS:IN POS:WDT POS:RB POS:VBN POS:NN POS:VBD POS:NN POS:NN POS:TO POS:DT POS:JJ POS:NN POS:, POS:RB POS:CD POS:NN POS:NN POS:CD POS:. 
[sentNum: 149]<Annotation Id="161005" Type="Sentence" StartNode="19180" EndNode="19486">These older trials likely underestimate the actual magnitude of overdiagnosis associated with modern screening mammography programs, given the increasing sensi­tivity of newer technologies, but together, they suggest that over a 10-year period, approximately 19% of breast cancers are overdiagnosed (2, 4). PreferredName:Old SemanticType:[tmco] PreferredName:Clinical Trials SemanticType:[resa] PreferredName:Degree or extent SemanticType:[qnco] PreferredName:overdiagnosis SemanticType:[fndg] PreferredName:Probably SemanticType:[idcn] PreferredName:Actual SemanticType:[qlco] PreferredName:Programs - Publication Format SemanticType:[inpr] PreferredName:GIVEN SemanticType:[cnce] PreferredName:Associated with SemanticType:[qlco] PreferredName:Screening mammography SemanticType:[topp] PreferredName:Together SemanticType:[qlco] PreferredName:suggestion SemanticType:[idcn] PreferredName:Increasing SemanticType:[ftcn] PreferredName:new technology SemanticType:[inpr] PreferredName:Approximate SemanticType:[qlco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:per year SemanticType:[tmco] PreferredName:Period (temporal qualifier) SemanticType:[tmco] PreferredName:Integer +2 SemanticType:[qnco] POS:JJR POS:NNS POS:DT POS:DT POS:JJ POS:JJ POS:VBP POS:NN POS:VBN POS:NN POS:IN POS:NN POS:NN POS:IN POS:JJ POS:VBN POS:DT POS:NNS POS:, POS:IN POS:JJR POS:VBG POS:NN POS:CC POS:RB POS:NNS POS:, POS:VBP POS:IN POS:, POS:PRP POS:CD POS:: POS:IN POS:DT POS:, POS:RB POS:NN POS:NN POS:IN POS:NN POS:CD POS:NN POS:VBN POS:NN POS:NNS POS:VBP POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 150]<Annotation Id="161010" Type="Sentence" StartNode="20314" EndNode="20495">Recurrent radiation exposure from a lifetime pro­gramofmammographyscreeningmayslightlyincrease theriskforbreastcancer,although noempiricalstudies have directly measured this effect. PreferredName:Proline SemanticType:[aapp, bacs] PreferredName:Direct (qualifier) SemanticType:[qlco] PreferredName:Recurrent SemanticType:[tmco] PreferredName:Exposure to radiation SemanticType:[phpr] PreferredName:Measured SemanticType:[qlco] PreferredName:Effect, Appearance SemanticType:[qlco] POS:NN POS:NN POS:JJ POS:NN POS:NN POS:IN POS:DT POS:IN POS:NNS POS:NN POS:, POS:VBN POS:DT POS:VBP POS:RB POS:NN POS:. 
[sentNum: 151]<Annotation Id="161011" Type="Sentence" StartNode="20496" EndNode="20754">Simulation models performed in support of this scienti.c report estimate that the mean lifetime attributable risk (LAR) of radiation-induced breast cancer from biennial screen­ing mammography in women aged 50 to 74 years is 3 cases per 10 000 women screened. PreferredName:Simulation SemanticType:[resa] PreferredName:Model SemanticType:[inpr] PreferredName:Reporting SemanticType:[hlca] PreferredName:Estimated SemanticType:[qnco] PreferredName:Performed SemanticType:[ftcn] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Attribution SemanticType:[menp] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:From SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Induce (action) SemanticType:[ftcn] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:year SemanticType:[tmco] PreferredName:Mammography SemanticType:[diap] PreferredName:Woman SemanticType:[popg] PreferredName:Woman SemanticType:[popg] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:One Thousand SemanticType:[qnco] POS:. POS:NN POS:DT POS:NN POS:IN POS:DT POS:NN POS:NN POS:JJ POS:NN POS:NN POS:NN POS:NN POS:IN POS:CD POS:NN POS:NN POS:IN POS:JJ POS:NN POS:NN POS:IN POS:JJ POS:VBG POS:CD POS:TO POS:NNS POS:JJ POS:VBZ POS:CD POS:CD POS:NNS POS:CD POS:CD POS:NNS POS:IN POS:. POS:NNS POS:VBN POS:NN POS:NNS POS:NN POS:IN POS:VBN POS:IN 
[sentNum: 152]<Annotation Id="161008" Type="Sentence" StartNode="20007" EndNode="20268">Most importantly, 4 of the 6 models assumed that all diag­nosed invasive cancer can progress to lethality; only 1 (model W) allowed for the possibility of cancer with &#x201c;limited malignant potential,&#x201d; whereby the tumor stops progressing at an early invasive stage. PreferredName:Most SemanticType:[qnco] PreferredName:Cancer of Nose SemanticType:[neop] PreferredName:Invasive SemanticType:[qlco] PreferredName:Model SemanticType:[inpr] PreferredName:Assumed SemanticType:[inpr] PreferredName:Singular SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] PreferredName:Progress SemanticType:[ftcn] PreferredName:Lethal SemanticType:[fndg] PreferredName:Primary malignant neoplasm SemanticType:[neop] PreferredName:Limited (extensiveness) SemanticType:[ftcn] PreferredName:allowing SemanticType:[socb] PreferredName:Possibly Related to Intervention SemanticType:[qlco] PreferredName:Neoplasm SemanticType:[neop] PreferredName:Stops device SemanticType:[mnob] PreferredName:Malignant Paraganglionic Neoplasm SemanticType:[neop] PreferredName:Potential SemanticType:[qlco] PreferredName:Invasive SemanticType:[qlco] PreferredName:Progressive SemanticType:[ftcn] PreferredName:Limited stage (cancer stage) SemanticType:[clas] POS:RBS POS:RB POS:IN POS:DT POS:, POS:CD POS:VBD POS:IN POS:CD POS:NNS POS:JJ POS:NN POS:DT POS:JJ POS:TO POS:NN POS:MD POS:VB POS:CD POS:CD POS:: POS:RB POS:NN POS:VBN POS:NN POS:NN POS:NN POS:IN POS:IN POS:DT POS:NN POS:JJ POS:NN POS:IN POS:, POS:CD POS:JJ POS:NN POS:NN POS:VBZ POS:WRB POS:DT POS:DT POS:JJ POS:VBG POS:IN POS:. POS:JJ POS:NN 
[sentNum: 153]<Annotation Id="161009" Type="Sentence" StartNode="20269" EndNode="20311">In addition, 1 of the models omitted DCIS. PreferredName:Add - instruction imperative SemanticType:[ftcn] PreferredName:omit SemanticType:[idcn] PreferredName:Noninfiltrating Intraductal Carcinoma SemanticType:[neop] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Model SemanticType:[inpr] POS:IN POS:CD POS:IN POS:NN POS:, POS:VBN POS:NNS POS:DT POS:NNS POS:. 
[sentNum: 154]<Annotation Id="161014" Type="Sentence" StartNode="21078" EndNode="21300">Of note, women with large breasts, who may re­quire extra views&#x2014;and thus higher radiation doses&#x2014;for complete mammography examination, seem to be at increased risk for radiation-induced breast cancer or breast cancer death. PreferredName:Woman SemanticType:[popg] PreferredName:Macromastia SemanticType:[fndg] PreferredName:Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider} SemanticType:[clna] PreferredName:Therapeutic radiology procedure SemanticType:[topp] PreferredName:Complete SemanticType:[qlco] PreferredName:View SemanticType:[spco] PreferredName:High dose SemanticType:[qnco] PreferredName:Exist SemanticType:[cnce] PreferredName:Increase SemanticType:[ftcn] PreferredName:Mammography SemanticType:[diap] PreferredName:To SemanticType:[qlco] PreferredName:Entire breast SemanticType:[bpoc] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Risk SemanticType:[qlco] PreferredName:Radiation-Induced Cancer SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] POS:IN POS:NNS POS:IN POS:NN POS:, POS:, POS:WP POS:JJ POS:NNS POS:JJ POS:NN POS:MD POS:VB POS:NN POS:NN POS:RB POS:JJR POS:NN POS:, POS:JJ POS:NN POS:VB POS:IN POS:VBP POS:TO POS:IN POS:JJ POS:VBN POS:NN POS:CC POS:NN POS:NN POS:NN POS:. POS:NN POS:NN 
[sentNum: 155]<Annotation Id="161015" Type="Sentence" StartNode="21301" EndNode="21536">Based on information from the Digital Mammography Imaging Screening Trial (which compared the test characteristics of .lm vs. digital mammography) (41), as no representative population-based data areavailable, anestimated 5% to6%ofU.S. PreferredName:Information SemanticType:[idcn] PreferredName:digital imaging SemanticType:[mcha] PreferredName:Base - General Qualifier SemanticType:[idcn] PreferredName:Comparison SemanticType:[acty] PreferredName:Laboratory Procedures SemanticType:[lbpr] PreferredName:Mammography SemanticType:[diap] PreferredName:Screening Study SemanticType:[resa] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Representation (action) SemanticType:[acty] PreferredName:Characteristics SemanticType:[qlco] PreferredName:Units Of Measure - lumen SemanticType:[qnco] PreferredName:Data SemanticType:[idcn] PreferredName:Population Group SemanticType:[popg] PreferredName:Base - General Qualifier SemanticType:[idcn] POS:VBN POS:IN POS:DT POS:IN POS:NN POS:NNP POS:NNP POS:NNP POS:NN POS:WDT POS:VBD POS:NNP POS:NN POS:NNS POS:IN POS:DT POS:NN POS:CC POS:. POS:. POS:NN POS:NN POS:CD POS:JJ POS:NN POS:, POS:IN POS:CD POS:NN POS:JJ POS:NNS POS:DT POS:JJ POS:JJ POS:CD POS:JJ POS:, POS:CD POS:NN POS:NN POS:TO POS:NN POS:. POS:NN POS:. 
[sentNum: 156]<Annotation Id="161012" Type="Sentence" StartNode="20755" EndNode="20830">The mean LAR of breast cancer death is 0.5 deaths per 10000 women screened. PreferredName:Attribution SemanticType:[menp] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Woman SemanticType:[popg] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:0/5 SemanticType:[qnco] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:DT POS:IN POS:NN POS:NN POS:NN POS:VBZ POS:CD POS:NN POS:NN POS:NNS POS:IN POS:. POS:CD POS:VBN POS:. POS:CD POS:NNS 
[sentNum: 157]<Annotation Id="161013" Type="Sentence" StartNode="20831" EndNode="21077">If biennial screening begins at age 40 in­stead of 50 years, the mean LAR of developing breast cancer increases to 4 cases per 10 000 women screened, and the number of breast cancer deaths in­creases to about 1 per 10 000 women screened (25, 26). PreferredName:Beginning SemanticType:[tmco] PreferredName:Age SemanticType:[orga] PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:year SemanticType:[tmco] PreferredName:Population Mean SemanticType:[qnco] PreferredName:/40 SemanticType:[tmco] PreferredName:Within SemanticType:[spco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Increase SemanticType:[ftcn] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Attribution SemanticType:[menp] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Numbers SemanticType:[qnco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Woman SemanticType:[popg] PreferredName:Within SemanticType:[spco] PreferredName:Woman SemanticType:[popg] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:NN POS:VBZ POS:IN POS:JJ POS:CD POS:NN POS:IN POS:NN POS:NNS POS:, POS:IN POS:CD POS:NN POS:IN POS:DT POS:NN POS:NN POS:VBZ POS:VBG POS:NN POS:NNS POS:IN POS:TO POS:CD POS:NNS POS:VBN POS:CD POS:CD POS:DT POS:NN POS:, POS:CC POS:NN POS:NNS POS:IN POS:NN POS:IN POS:CD POS:NNS POS:TO POS:CD POS:NNS POS:IN POS:CD POS:CD POS:, POS:VBN POS:RB POS:. POS:CD POS:NN 
[sentNum: 158]<Annotation Id="161018" Type="Sentence" StartNode="21953" EndNode="21979">Primary Screening With DBT PreferredName:Aspects of disease screening SemanticType:[ftcn] PreferredName:DBT gene SemanticType:[gngm] PreferredName:True primary (qualifier value) SemanticType:[tmco] POS:VBG POS:IN POS:JJ POS:NNP 
[sentNum: 159]<Annotation Id="161019" Type="Sentence" StartNode="21982" EndNode="22079">Currently, DBT is most frequently performed in combination with conventional digital mammography; PreferredName:Most SemanticType:[qnco] PreferredName:Frequent SemanticType:[tmco] PreferredName:Current (present time) SemanticType:[tmco] PreferredName:DBT gene SemanticType:[gngm] PreferredName:classical example SemanticType:[qlco] PreferredName:Digital Mammography SemanticType:[diap] PreferredName:Performed SemanticType:[ftcn] PreferredName:Combined SemanticType:[qlco] POS:, POS:NNP POS:RB POS:RB POS:VBN POS:VBZ POS:RBS POS:IN POS:JJ POS:IN POS:NN POS:: POS:JJ POS:NN 
[sentNum: 160]<Annotation Id="161016" Type="Sentence" StartNode="21537" EndNode="21622">women will require additional views during screening for complete breast examination. PreferredName:Woman SemanticType:[popg] PreferredName:Complete SemanticType:[qlco] PreferredName:Examination of breast SemanticType:[diap] PreferredName:Additional SemanticType:[ftcn] PreferredName:Views screening SemanticType:[orga] POS:VB POS:JJ POS:NNS POS:MD POS:NN POS:IN POS:NNS POS:IN POS:NN POS:. POS:JJ POS:NN 
[sentNum: 161]<Annotation Id="161017" Type="Sentence" StartNode="21623" EndNode="21950">For biennial screen­ing in women aged 50 to 74 years, the mean LAR of developing breast cancer is an estimated 6 versus 2 cases per 10 000 screened women with and without largebreasts,respectively;the mean LARofbreast can­cer death is 1 versus 0.4 deaths per 10000 screened womenwithandwithoutlargebreasts,respectively(25, 26). PreferredName:Woman SemanticType:[popg] PreferredName:Elderly (population group) SemanticType:[popg] PreferredName:Preposition For SemanticType:[qlco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Lifetime Risk SemanticType:[qnco] PreferredName:Attribution SemanticType:[menp] PreferredName:year SemanticType:[tmco] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Integer +2 SemanticType:[qnco] PreferredName:Case unit dose SemanticType:[qnco] PreferredName:Malignant neoplasm of breast SemanticType:[neop] PreferredName:Estimated SemanticType:[qnco] PreferredName:And SemanticType:[idcn] PreferredName:Population Mean SemanticType:[qnco] PreferredName:Screening - procedure intent SemanticType:[ftcn] PreferredName:Woman SemanticType:[popg] PreferredName:1+ Score SemanticType:[qnco] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:CER tumor staging notation SemanticType:[inpr] PreferredName:Cessation of life SemanticType:[orgf] PreferredName:Screening - procedure intent SemanticType:[ftcn] POS:NN POS:IN POS:IN POS:JJ POS:CD POS:TO POS:NNS POS:JJ POS:, POS:DT POS:CD POS:NNS POS:IN POS:VBG POS:NN POS:NN POS:VBZ POS:DT POS:NN POS:NN POS:CC POS:CD POS:VBN POS:CD POS:CD POS:CD POS:NNS POS:IN POS:IN POS:CC POS:VBN POS:NNS POS:, POS:RB POS:IN POS:NNS POS:NN POS:NN POS:: POS:DT POS:VBZ POS:CD POS:NN POS:NN POS:. POS:CD POS:CC POS:CD POS:CD POS:VBN POS:NNS POS:IN POS:RB POS:CD POS:NNS POS:, POS:CD POS:NN POS:CD POS:, POS:. 
[sentNum: 162]<Annotation Id="161022" Type="Sentence" StartNode="22129" EndNode="22164">4 &#x2022; 16 February 2016 www.annals.org PreferredName:Internet SemanticType:[mnob] PreferredName:Professional Organization or Group SemanticType:[prog] POS:CD POS:CD POS:CD POS:NN POS:CD POS:NNP POS:. POS:NN POS:. POS:NN 
[sentNum: 163]<Annotation Id="161023" Type="Sentence" StartNode="22175" EndNode="22221">Screening for Breast Cancer CLINICAL GUIDELINE PreferredName:Guidelines SemanticType:[inpr] PreferredName:Screening for malignant neoplasm of breast SemanticType:[topp] PreferredName:Clinical SemanticType:[qlco] POS:NN POS:NN POS:VBG POS:IN POS:NN POS:NN 
[sentNum: 164]<Annotation Id="161020" Type="Sentence" StartNode="22082" EndNode="22120">290 Annals of Internal Medicine &#x2022; Vol. PreferredName:Internal medicine physicians SemanticType:[inpr] PreferredName:Volume SemanticType:[qnco] POS:CD POS:JJ POS:NN POS:NNS POS:IN POS:. POS:NN POS:NN 
[sentNum: 165]<Annotation Id="161021" Type="Sentence" StartNode="22121" EndNode="22128">164 No. POS:CD POS:DT POS:. 
[sentNum: 166]<Annotation Id="161026" Type="Sentence" StartNode="22425" EndNode="22541">The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF. PreferredName:United States SemanticType:[geoa] PreferredName:Supportive assistance SemanticType:[cnce] PreferredName:Surgical aspects SemanticType:[ftcn] PreferredName:Congress (U.S. Legislature) SemanticType:[orgt] PreferredName:United States Agency for Healthcare Research and Quality SemanticType:[hcro] POS:DT POS:NNP POS:. POS:NNP POS:. POS:NN POS:DT POS:NNP POS:VBZ POS:IN POS:NNP POS:CC POS:IN POS:NNP POS:DT POS:NNS POS:NNP POS:VBP POS:NNP POS:. POS:IN POS:DT 
[sentNum: 167]<Annotation Id="161027" Type="Sentence" StartNode="22544" EndNode="22741">Disclosures: Dr. Phillips disclosed that he has received past grants and contracts from NCI and CDC for research on pat­terns of use of screening tests for breast and other cancers in primary care. PreferredName:Receive SemanticType:[qlco] PreferredName:Past SemanticType:[tmco] PreferredName:Disclosure SemanticType:[inbe] PreferredName:Physicians SemanticType:[prog] PreferredName:National Cancer Institute SemanticType:[hcro] PreferredName:Centers for Disease Control and Prevention (U.S.) SemanticType:[hcro] PreferredName:funding grant SemanticType:[qnco] PreferredName:Contract agreement SemanticType:[inpr] PreferredName:Tern (organism) SemanticType:[bird] PreferredName:Use of SemanticType:[ftcn] PreferredName:Research Activities SemanticType:[resa] PreferredName:On (qualifier value) SemanticType:[inpr] PreferredName:Other SemanticType:[qlco] PreferredName:cancer care SemanticType:[topp] PreferredName:Screening Tests SemanticType:[hlca] PreferredName:Entire breast SemanticType:[bpoc] POS:NN POS:. POS:NNS POS:: POS:IN POS:PRP POS:NNP POS:VBD POS:IN POS:NNS POS:VBZ POS:VBN POS:IN POS:NN POS:CC POS:NNS POS:IN POS:NN POS:CC POS:NNP POS:IN POS:NN POS:IN POS:NNS POS:NNS POS:IN POS:IN POS:NN POS:JJ POS:NNS POS:NN POS:CC POS:NN POS:. POS:IN POS:JJ 
[sentNum: 168]<Annotation Id="161024" Type="Sentence" StartNode="22224" EndNode="22357">strued as an of.cial position of the Agency for Healthcare Re­search and Quality or the U.S. Department of Health and Human Services. PreferredName:Positioning Attribute SemanticType:[spco] PreferredName:Respiratory Domain SemanticType:[idcn] PreferredName:Search - action SemanticType:[acty] PreferredName:Agencies SemanticType:[orgt] PreferredName:Health Care SemanticType:[hlca] PreferredName:United States Dept. of Health and Human Services SemanticType:[hcro] PreferredName:Quality SemanticType:[qlco] PreferredName:United States SemanticType:[geoa] POS:VBN POS:IN POS:. POS:JJ POS:DT POS:IN POS:DT POS:NNP POS:NN POS:IN POS:NNP POS:CC POS:IN POS:NNP POS:DT POS:NNP POS:NNP POS:CC POS:. POS:NNP POS:. POS:NN POS:CC POS:NNP POS:IN POS:NNP POS:NNPS POS:. 
[sentNum: 169]<Annotation Id="161025" Type="Sentence" StartNode="22360" EndNode="22424">Financial Support: The USPSTF is an independent, voluntary body. PreferredName:Financial Support SemanticType:[idcn] PreferredName:Human body SemanticType:[humn] PreferredName:Independence SemanticType:[idcn] PreferredName:Voluntary SemanticType:[inbe] POS:NNP POS:NN POS:NN POS:VBZ POS:: POS:DT POS:, POS:JJ POS:DT POS:JJ POS:NN POS:. 
[sentNum: 170]<Annotation Id="161030" Type="Sentence" StartNode="22965" EndNode="23047">Forms can be viewed at www.acponline.org/authors/icmje/ Con.ictOfInterestForms.do?msNumPreferredName:Qualitative form SemanticType:[qlco] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:Journalist SemanticType:[prog] PreferredName:View SemanticType:[spco] PreferredName:Internet SemanticType:[mnob] POS:NNS POS:VBN POS:IN POS:MD POS:VB POS:NN POS:. POS:NN POS:. POS:NNS POS:: POS:NN POS:: POS:NN POS:. POS:JJ POS:: POS:VB POS:. POS:NNPS POS:. 
[sentNum: 171]<Annotation Id="161031" Type="Sentence" StartNode="23047" EndNode="23062">msNum=M15-2886. PreferredName:M15 Message Structure SemanticType:[inpr] POS:NN POS:CD POS:NN POS:JJ POS:. POS:: POS:CD 
[sentNum: 172]<Annotation Id="161028" Type="Sentence" StartNode="22742" EndNode="22820">Dr. owens discloses that he has received travel reimbursement from the USPSTF. PreferredName:Act Code - travel SemanticType:[idcn] PreferredName:Physicians SemanticType:[prog] PreferredName:Receive SemanticType:[qlco] POS:NNS POS:VBZ POS:NN POS:. POS:VBZ POS:VBN POS:IN POS:PRP POS:IN POS:DT POS:NN POS:NN POS:NNP POS:. 
[sentNum: 173]<Annotation Id="161029" Type="Sentence" StartNode="22821" EndNode="22964">Authors followed the policy regarding con.icts of interest described at www.uspreventive servicestaskforce.org/Page/Name/methods-and-processes. PreferredName:Journalist SemanticType:[prog] PreferredName:COPPER TOXICOSIS, IDIOPATHIC SemanticType:[dsyn] PreferredName:Interested SemanticType:[menp] PreferredName:Followed by SemanticType:[tmco] PreferredName:Policy SemanticType:[inpr] PreferredName:Professional Organization or Group SemanticType:[prog] PreferredName:Page (document) SemanticType:[inpr] PreferredName:described SemanticType:[idcn] PreferredName:Internet SemanticType:[mnob] PreferredName:Processed SemanticType:[phpr] PreferredName:Person Name SemanticType:[inpr] PreferredName:Methods aspects SemanticType:[inpr] POS:NNS POS:VBD POS:VBG POS:NN POS:DT POS:NN POS:IN POS:NN POS:. POS:NNS POS:NN POS:. POS:VBN POS:IN POS:. POS:NN POS:JJ POS:NN POS:: POS:VB POS:: POS:NNP POS:. POS:: POS:NNS 
